HRP20000917A2 - Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases - Google Patents
Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases Download PDFInfo
- Publication number
- HRP20000917A2 HRP20000917A2 HR20000917A HRP20000917A HRP20000917A2 HR P20000917 A2 HRP20000917 A2 HR P20000917A2 HR 20000917 A HR20000917 A HR 20000917A HR P20000917 A HRP20000917 A HR P20000917A HR P20000917 A2 HRP20000917 A2 HR P20000917A2
- Authority
- HR
- Croatia
- Prior art keywords
- phenyl
- ureido
- methyl
- butyl
- propionic acid
- Prior art date
Links
- 230000002757 inflammatory effect Effects 0.000 title claims description 13
- 208000023275 Autoimmune disease Diseases 0.000 title claims description 12
- 208000027866 inflammatory disease Diseases 0.000 title claims description 12
- 208000023504 respiratory system disease Diseases 0.000 title claims description 10
- 230000001363 autoimmune Effects 0.000 title claims description 9
- 230000027455 binding Effects 0.000 title description 18
- 239000003112 inhibitor Substances 0.000 title description 17
- 230000001419 dependent effect Effects 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims description 223
- -1 triaznyl Chemical group 0.000 claims description 129
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 124
- 230000036961 partial effect Effects 0.000 claims description 77
- 125000000623 heterocyclic group Chemical group 0.000 claims description 65
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical group FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 63
- 125000003118 aryl group Chemical group 0.000 claims description 61
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims description 54
- 125000001424 substituent group Chemical group 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 47
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 45
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 41
- 125000001072 heteroaryl group Chemical group 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 17
- 239000004202 carbamide Substances 0.000 claims description 17
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 13
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 13
- 229910052757 nitrogen Chemical group 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 235000019260 propionic acid Nutrition 0.000 claims description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 208000006673 asthma Diseases 0.000 claims description 8
- 150000001721 carbon Chemical group 0.000 claims description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 7
- 125000004414 alkyl thio group Chemical group 0.000 claims description 7
- 125000002837 carbocyclic group Chemical group 0.000 claims description 7
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 125000002971 oxazolyl group Chemical group 0.000 claims description 7
- 230000001717 pathogenic effect Effects 0.000 claims description 7
- 125000004193 piperazinyl group Chemical group 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 239000003018 immunosuppressive agent Substances 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000002757 morpholinyl group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- BBBSYNRZZATAHL-UHFFFAOYSA-N 3-[2-[1-[[2-[4-[(2,6-dichlorophenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,3-thiazol-5-yl]propanoic acid Chemical compound N=1C=C(CCC(O)=O)SC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=C(Cl)C=CC=C1Cl BBBSYNRZZATAHL-UHFFFAOYSA-N 0.000 claims description 5
- RZLHHEMDVRXMLF-UHFFFAOYSA-N 3-[2-[1-[[2-[4-[(2-fluorophenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,3-thiazol-5-yl]propanoic acid Chemical compound N=1C=C(CCC(O)=O)SC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1F RZLHHEMDVRXMLF-UHFFFAOYSA-N 0.000 claims description 5
- YVUDZGKPSPCYKB-UHFFFAOYSA-N 3-[3-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-1,2-oxazol-5-yl]propanoic acid Chemical compound C1=C(CCC(O)=O)ON=C1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C YVUDZGKPSPCYKB-UHFFFAOYSA-N 0.000 claims description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 5
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 239000000924 antiasthmatic agent Substances 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000004494 ethyl ester group Chemical group 0.000 claims description 5
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 239000011593 sulfur Chemical group 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- FXAUFLVCVWYGLK-UHFFFAOYSA-N 3-[2-[1-[[2-[4-[(2-methoxyphenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,3-thiazol-5-yl]propanoic acid Chemical compound COC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)NC(CC(C)C)C1=NC=C(CCC(O)=O)S1 FXAUFLVCVWYGLK-UHFFFAOYSA-N 0.000 claims description 4
- BFSPATRZTOUXBI-UHFFFAOYSA-N 3-[2-[1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-1,3-thiazol-5-yl]propanoic acid Chemical compound N=1C=C(CCC(O)=O)SC=1C(CCC)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C BFSPATRZTOUXBI-UHFFFAOYSA-N 0.000 claims description 4
- RTTRCNDKNNRWCA-UHFFFAOYSA-N 3-[2-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-1,3-oxazol-5-yl]propanoic acid Chemical compound N=1C=C(CCC(O)=O)OC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C RTTRCNDKNNRWCA-UHFFFAOYSA-N 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 230000001088 anti-asthma Effects 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 230000023578 negative regulation of cell adhesion Effects 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 claims description 3
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims description 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 3
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 3
- MDSLYHPULFIAMH-UHFFFAOYSA-N 3-[2-[1-[[2-[4-[(2,6-dimethylphenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,3-thiazol-5-yl]propanoic acid Chemical compound N=1C=C(CCC(O)=O)SC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=C(C)C=CC=C1C MDSLYHPULFIAMH-UHFFFAOYSA-N 0.000 claims description 3
- KEAXJEQRYYKKFH-UHFFFAOYSA-N 3-[2-[1-[[2-[4-[(2-chloro-6-methylphenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,3-thiazol-5-yl]propanoic acid Chemical compound N=1C=C(CCC(O)=O)SC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=C(C)C=CC=C1Cl KEAXJEQRYYKKFH-UHFFFAOYSA-N 0.000 claims description 3
- RMWCQFDACWYJLG-UHFFFAOYSA-N 3-[2-[1-[[2-[4-[(2-chlorophenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,3-thiazol-5-yl]propanoic acid Chemical compound N=1C=C(CCC(O)=O)SC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1Cl RMWCQFDACWYJLG-UHFFFAOYSA-N 0.000 claims description 3
- QKPOGBUYUXZUJA-UHFFFAOYSA-N 3-[2-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-1,3-thiazol-5-yl]-n-methylsulfonylpropanamide Chemical compound N=1C=C(CCC(=O)NS(C)(=O)=O)SC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C QKPOGBUYUXZUJA-UHFFFAOYSA-N 0.000 claims description 3
- WSDUIYINORQGPC-UHFFFAOYSA-N 3-[5-[1-[[2-[4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]-3-methoxyphenyl]acetyl]amino]-3-methylbutyl]-1h-imidazol-2-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CN=2)C2CCCC2)C(OC)=CC=1CC(=O)NC(CC(C)C)C1=CNC(CCC(O)=O)=N1 WSDUIYINORQGPC-UHFFFAOYSA-N 0.000 claims description 3
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- LUBJCRLGQSPQNN-UHFFFAOYSA-N Z-phenylurea Natural products NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 230000000340 anti-metabolite Effects 0.000 claims description 3
- 229940100197 antimetabolite Drugs 0.000 claims description 3
- 239000002256 antimetabolite Substances 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 229940124630 bronchodilator Drugs 0.000 claims description 3
- 239000000168 bronchodilator agent Substances 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 claims description 3
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 claims description 3
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims description 3
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 3
- 239000003022 immunostimulating agent Substances 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- XHPVQRLTDCIBIC-UHFFFAOYSA-N n-hydroxy-3-[2-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-1,3-thiazol-5-yl]propanamide Chemical compound N=1C=C(CCC(=O)NO)SC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C XHPVQRLTDCIBIC-UHFFFAOYSA-N 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 3
- 125000000466 oxiranyl group Chemical group 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 229960001940 sulfasalazine Drugs 0.000 claims description 3
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 claims description 2
- 125000005955 1H-indazolyl group Chemical group 0.000 claims description 2
- HKNJVYSGXGQOBT-UHFFFAOYSA-N 2-[2-[1-[[2-[3-fluoro-4-(pyridin-2-ylcarbamoylamino)phenyl]acetyl]amino]-3-methylbutyl]-4,5-dihydro-1,3-thiazol-5-yl]acetic acid Chemical compound N=1CC(CC(O)=O)SC=1C(CC(C)C)NC(=O)CC(C=C1F)=CC=C1NC(=O)NC1=CC=CC=N1 HKNJVYSGXGQOBT-UHFFFAOYSA-N 0.000 claims description 2
- KZJAGLOMTHMYMO-UHFFFAOYSA-N 2-[2-[1-[[2-[4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]-3-fluorophenyl]acetyl]amino]-3-methylbutyl]-1h-imidazol-5-yl]acetic acid Chemical compound N=1C(CC(O)=O)=CNC=1C(CC(C)C)NC(=O)CC(C=C1F)=CC=C1NC(=O)NC1=NC=CC=C1C1CCCC1 KZJAGLOMTHMYMO-UHFFFAOYSA-N 0.000 claims description 2
- OYKCAJWTKPUWAN-UHFFFAOYSA-N 2-[3-[1-[[2-[4-[(2-cyclopentylphenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,2-oxazol-5-yl]acetic acid Chemical compound C1=C(CC(O)=O)ON=C1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C1CCCC1 OYKCAJWTKPUWAN-UHFFFAOYSA-N 0.000 claims description 2
- LMFDUXIMWCOWSR-UHFFFAOYSA-N 2-[3-[3-methyl-1-[[2-[3-methyl-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]pyrazol-1-yl]acetic acid Chemical compound C1=CN(CC(O)=O)N=C1C(CC(C)C)NC(=O)CC(C=C1C)=CC=C1NC(=O)NC1=CC=CC=C1C LMFDUXIMWCOWSR-UHFFFAOYSA-N 0.000 claims description 2
- HQELISSMUREGCO-UHFFFAOYSA-N 2-[4-[2-[3-methyl-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-3-(2-methylpropyl)-2-oxopiperazin-1-yl]acetic acid Chemical compound C1CN(CC(O)=O)C(=O)C(CC(C)C)N1C(=O)CC(C=C1C)=CC=C1NC(=O)NC1=CC=CC=C1C HQELISSMUREGCO-UHFFFAOYSA-N 0.000 claims description 2
- YQEWDJZFRMCHCD-UHFFFAOYSA-N 2-[4-[2-[3-methyl-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-5-(2-methylpropyl)-2-oxopiperazin-1-yl]acetic acid Chemical compound CC(C)CC1CN(CC(O)=O)C(=O)CN1C(=O)CC(C=C1C)=CC=C1NC(=O)NC1=CC=CC=C1C YQEWDJZFRMCHCD-UHFFFAOYSA-N 0.000 claims description 2
- KGWBRKSBWROZCP-UHFFFAOYSA-N 2-[4-[3-methyl-1-[[2-[3-methyl-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-3h-1,2,4-triazol-2-yl]acetic acid Chemical compound C1N(CC(O)=O)N=CN1C(CC(C)C)NC(=O)CC(C=C1C)=CC=C1NC(=O)NC1=CC=CC=C1C KGWBRKSBWROZCP-UHFFFAOYSA-N 0.000 claims description 2
- UWLYYQUCCHBVCV-UHFFFAOYSA-N 2-[4-[3-methyl-1-[[2-[3-methyl-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-5h-tetrazol-1-yl]acetic acid Chemical compound C1N(CC(O)=O)N=NN1C(CC(C)C)NC(=O)CC(C=C1C)=CC=C1NC(=O)NC1=CC=CC=C1C UWLYYQUCCHBVCV-UHFFFAOYSA-N 0.000 claims description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 2
- QXCBVQQLKIRGPY-UHFFFAOYSA-N 3-[2-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-3,6-dihydro-2h-pyridin-2-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2OC(CCC(O)=O)=CN=2)CC=CC1 QXCBVQQLKIRGPY-UHFFFAOYSA-N 0.000 claims description 2
- OVXCRIQYLIKODD-UHFFFAOYSA-N 3-[2-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-3,6-dihydro-2h-pyridin-2-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2SC(CCC(O)=O)=CN=2)CC=CC1 OVXCRIQYLIKODD-UHFFFAOYSA-N 0.000 claims description 2
- YGEXROMPQRXWFF-UHFFFAOYSA-N 3-[2-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-4-oxopyrrolidin-2-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2OC(CCC(O)=O)=CN=2)CC(=O)C1 YGEXROMPQRXWFF-UHFFFAOYSA-N 0.000 claims description 2
- OOOOEAQYOYXRAG-UHFFFAOYSA-N 3-[2-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-4-oxopyrrolidin-2-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2SC(CCC(O)=O)=CN=2)CC(=O)C1 OOOOEAQYOYXRAG-UHFFFAOYSA-N 0.000 claims description 2
- WSSBXMIOMQEUNH-UHFFFAOYSA-N 3-[2-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]azepan-2-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2OC(CCC(O)=O)=CN=2)CCCCC1 WSSBXMIOMQEUNH-UHFFFAOYSA-N 0.000 claims description 2
- BZYGOAXWORSNJE-UHFFFAOYSA-N 3-[2-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]azepan-2-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2SC(CCC(O)=O)=CN=2)CCCCC1 BZYGOAXWORSNJE-UHFFFAOYSA-N 0.000 claims description 2
- AQBDBLGEEJMJTQ-UHFFFAOYSA-N 3-[2-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]azetidin-2-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2OC(CCC(O)=O)=CN=2)CC1 AQBDBLGEEJMJTQ-UHFFFAOYSA-N 0.000 claims description 2
- CKEIFTKSXLGCGV-UHFFFAOYSA-N 3-[2-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]azetidin-2-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2SC(CCC(O)=O)=CN=2)CC1 CKEIFTKSXLGCGV-UHFFFAOYSA-N 0.000 claims description 2
- WUUFSFYYMDIAOS-UHFFFAOYSA-N 3-[2-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]piperidin-2-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2OC(CCC(O)=O)=CN=2)CCCC1 WUUFSFYYMDIAOS-UHFFFAOYSA-N 0.000 claims description 2
- KUNOQVYVRWSOST-UHFFFAOYSA-N 3-[2-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]piperidin-2-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2SC(CCC(O)=O)=CN=2)CCCC1 KUNOQVYVRWSOST-UHFFFAOYSA-N 0.000 claims description 2
- VBVCKPWBLMDHKX-UHFFFAOYSA-N 3-[2-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2OC(CCC(O)=O)=CN=2)CCC1 VBVCKPWBLMDHKX-UHFFFAOYSA-N 0.000 claims description 2
- NKUOOPQLEOZHLO-UHFFFAOYSA-N 3-[2-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2SC(CCC(O)=O)=CN=2)CCC1 NKUOOPQLEOZHLO-UHFFFAOYSA-N 0.000 claims description 2
- TTXXWZBESOGCGO-UHFFFAOYSA-N 3-[2-[1-[[2-[3-cyclopentyl-4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1h-imidazol-5-yl]propanoic acid Chemical compound N=1C=C(CCC(O)=O)NC=1C(CC(C)C)NC(=O)CC(C=C1C2CCCC2)=CC=C1NC(=O)NC1=NC=CC=C1C TTXXWZBESOGCGO-UHFFFAOYSA-N 0.000 claims description 2
- BVCQFTCEFZFPPH-UHFFFAOYSA-N 3-[2-[1-[[2-[3-fluoro-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,3-oxazol-5-yl]propanoic acid Chemical compound N=1C=C(CCC(O)=O)OC=1C(CC(C)C)NC(=O)CC(C=C1F)=CC=C1NC(=O)NC1=CC=CC=C1C BVCQFTCEFZFPPH-UHFFFAOYSA-N 0.000 claims description 2
- YQADRBXDPQSVOG-UHFFFAOYSA-N 3-[2-[1-[[2-[3-methoxy-4-(pyridin-2-ylcarbamoylamino)phenyl]acetyl]amino]-3-methylbutyl]-1,3-thiazol-5-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2N=CC=CC=2)C(OC)=CC=1CC(=O)NC(CC(C)C)C1=NC=C(CCC(O)=O)S1 YQADRBXDPQSVOG-UHFFFAOYSA-N 0.000 claims description 2
- OXXWTEQYSNSHGF-UHFFFAOYSA-N 3-[2-[1-[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,3-oxazol-4-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CC=2)C)C(OC)=CC=1CC(=O)NC(CC(C)C)C1=NC(CCC(O)=O)=CO1 OXXWTEQYSNSHGF-UHFFFAOYSA-N 0.000 claims description 2
- SYHBDPRCKKBBOL-UHFFFAOYSA-N 3-[2-[1-[[2-[3-methoxy-4-[(3-methoxypyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,1-dioxo-4,5-dihydro-1,3-thiazol-5-yl]propanoic acid Chemical compound COC1=CC=CN=C1NC(=O)NC(C(=C1)OC)=CC=C1CC(=O)NC(CC(C)C)C1=NCC(CCC(O)=O)S1(=O)=O SYHBDPRCKKBBOL-UHFFFAOYSA-N 0.000 claims description 2
- GRTPXUVKOKVLRJ-UHFFFAOYSA-N 3-[2-[1-[[2-[4-[(2-fluorophenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-4,5-dihydro-1,3-oxazol-5-yl]propanoic acid Chemical compound N=1CC(CCC(O)=O)OC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1F GRTPXUVKOKVLRJ-UHFFFAOYSA-N 0.000 claims description 2
- QNOKXJYHJKRMAS-UHFFFAOYSA-N 3-[2-[1-[[2-[4-[(2-methoxyphenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,3-oxazol-5-yl]propanoic acid Chemical compound COC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)NC(CC(C)C)C1=NC=C(CCC(O)=O)O1 QNOKXJYHJKRMAS-UHFFFAOYSA-N 0.000 claims description 2
- XGPZIWHMWJLJFK-UHFFFAOYSA-N 3-[2-[1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]but-3-enyl]-1,3-thiazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)NC(CC=C)C1=NC=C(CCC(O)=O)S1 XGPZIWHMWJLJFK-UHFFFAOYSA-N 0.000 claims description 2
- REZNXIFSUNEWLW-UHFFFAOYSA-N 3-[2-[1-[[2-[4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]-3-methoxyphenyl]acetyl]amino]-3-methylbutyl]-1h-imidazol-5-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CN=2)C2CCCC2)C(OC)=CC=1CC(=O)NC(CC(C)C)C1=NC=C(CCC(O)=O)N1 REZNXIFSUNEWLW-UHFFFAOYSA-N 0.000 claims description 2
- PAFDGPKDDLQEEI-UHFFFAOYSA-N 3-[2-[1-[[2-[4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]-3-methylphenyl]acetyl]amino]-3-methylbutyl]-4,5-dihydro-1h-imidazol-5-yl]propanoic acid Chemical compound N=1CC(CCC(O)=O)NC=1C(CC(C)C)NC(=O)CC(C=C1C)=CC=C1NC(=O)NC1=NC=CC=C1C1CCCC1 PAFDGPKDDLQEEI-UHFFFAOYSA-N 0.000 claims description 2
- WPPQXZAEBFKILN-UHFFFAOYSA-N 3-[2-[1-[[2-[4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-4,5-dihydro-1,3-oxazol-5-yl]propanoic acid Chemical compound N=1CC(CCC(O)=O)OC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=NC=CC=C1C1CCCC1 WPPQXZAEBFKILN-UHFFFAOYSA-N 0.000 claims description 2
- LQZIXUPIMJTKFX-UHFFFAOYSA-N 3-[2-[2-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-3,4-dihydro-1h-isoquinolin-3-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2OC(CCC(O)=O)=CN=2)CC2=CC=CC=C2C1 LQZIXUPIMJTKFX-UHFFFAOYSA-N 0.000 claims description 2
- RWCPRALTHYQQAB-UHFFFAOYSA-N 3-[2-[2-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-3,4-dihydro-1h-isoquinolin-3-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2SC(CCC(O)=O)=CN=2)CC2=CC=CC=C2C1 RWCPRALTHYQQAB-UHFFFAOYSA-N 0.000 claims description 2
- XEXWNSNTWQDNRP-UHFFFAOYSA-N 3-[2-[2-methyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2OC(CCC(O)=O)=CN=2)(C)CCC1 XEXWNSNTWQDNRP-UHFFFAOYSA-N 0.000 claims description 2
- LIODMWHVPRHDPS-UHFFFAOYSA-N 3-[2-[2-methyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2SC(CCC(O)=O)=CN=2)(C)CCC1 LIODMWHVPRHDPS-UHFFFAOYSA-N 0.000 claims description 2
- VMAIZGOIPYPSBA-UHFFFAOYSA-N 3-[2-[3,3-dimethyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2OC(CCC(O)=O)=CN=2)C(C)(C)CC1 VMAIZGOIPYPSBA-UHFFFAOYSA-N 0.000 claims description 2
- JEIVQTRZARKZSG-UHFFFAOYSA-N 3-[2-[3,3-dimethyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2SC(CCC(O)=O)=CN=2)C(C)(C)CC1 JEIVQTRZARKZSG-UHFFFAOYSA-N 0.000 claims description 2
- FJPWUMKJFSFKCE-UHFFFAOYSA-N 3-[2-[3-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-1,3-oxazolidin-4-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2SC(CCC(O)=O)=CN=2)COC1 FJPWUMKJFSFKCE-UHFFFAOYSA-N 0.000 claims description 2
- TXPZILOCEZPRTC-UHFFFAOYSA-N 3-[2-[3-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-1,3-thiazolidin-4-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2OC(CCC(O)=O)=CN=2)CSC1 TXPZILOCEZPRTC-UHFFFAOYSA-N 0.000 claims description 2
- IAMZQOBQJSODKL-UHFFFAOYSA-N 3-[2-[3-methyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound CC1CCN(C(=O)CC=2C=CC(NC(=O)NC=3C(=CC=CC=3)C)=CC=2)C1C1=NC=C(CCC(O)=O)O1 IAMZQOBQJSODKL-UHFFFAOYSA-N 0.000 claims description 2
- JQTLRJXOAJHBMW-UHFFFAOYSA-N 3-[2-[3-methyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound CC1CCN(C(=O)CC=2C=CC(NC(=O)NC=3C(=CC=CC=3)C)=CC=2)C1C1=NC=C(CCC(O)=O)S1 JQTLRJXOAJHBMW-UHFFFAOYSA-N 0.000 claims description 2
- FHEZXSCKPAOZPI-UHFFFAOYSA-N 3-[2-[3-methyl-1-[[2-[3-methyl-4-(pyridin-2-ylcarbamoylamino)phenyl]acetyl]amino]butyl]-4,5-dihydro-1,3-thiazol-4-yl]propanoic acid Chemical compound N=1C(CCC(O)=O)CSC=1C(CC(C)C)NC(=O)CC(C=C1C)=CC=C1NC(=O)NC1=CC=CC=N1 FHEZXSCKPAOZPI-UHFFFAOYSA-N 0.000 claims description 2
- GBDSSALQXWQVIW-UHFFFAOYSA-N 3-[2-[3-methyl-1-[[2-[3-methyl-4-(pyridin-2-ylcarbamoylamino)phenyl]acetyl]amino]butyl]-4,5-dihydro-1,3-thiazol-5-yl]propanoic acid Chemical compound N=1CC(CCC(O)=O)SC=1C(CC(C)C)NC(=O)CC(C=C1C)=CC=C1NC(=O)NC1=CC=CC=N1 GBDSSALQXWQVIW-UHFFFAOYSA-N 0.000 claims description 2
- UBKWCDVUBRNKBE-UHFFFAOYSA-N 3-[2-[3-methyl-1-[[2-[3-methyl-4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]butyl]-4,5-dihydro-1h-imidazol-5-yl]propanoic acid Chemical compound N=1CC(CCC(O)=O)NC=1C(CC(C)C)NC(=O)CC(C=C1C)=CC=C1NC(=O)NC1=NC=CC=C1C UBKWCDVUBRNKBE-UHFFFAOYSA-N 0.000 claims description 2
- UBDLHZOGVNEPRO-UHFFFAOYSA-N 3-[2-[3-methyl-1-[[2-[4-(pyridin-2-ylcarbamoylamino)phenyl]acetyl]amino]butyl]-1,3-oxazol-5-yl]propanoic acid Chemical compound N=1C=C(CCC(O)=O)OC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=N1 UBDLHZOGVNEPRO-UHFFFAOYSA-N 0.000 claims description 2
- BKEYTGRISNFZOL-UHFFFAOYSA-N 3-[2-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-1,3-oxazol-4-yl]propanoic acid Chemical compound N=1C(CCC(O)=O)=COC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C BKEYTGRISNFZOL-UHFFFAOYSA-N 0.000 claims description 2
- VJRNPNOHAFDGOX-UHFFFAOYSA-N 3-[2-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-4,5-dihydro-1,3-oxazol-4-yl]propanoic acid Chemical compound N=1C(CCC(O)=O)COC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C VJRNPNOHAFDGOX-UHFFFAOYSA-N 0.000 claims description 2
- SOYJYGKAABRXEF-UHFFFAOYSA-N 3-[2-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-4,5-dihydro-1,3-oxazol-5-yl]propanoic acid Chemical compound N=1CC(CCC(O)=O)OC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C SOYJYGKAABRXEF-UHFFFAOYSA-N 0.000 claims description 2
- PQKVHTPFCCCSQI-UHFFFAOYSA-N 3-[2-[4-(methylamino)-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound C1C(NC)CC(C=2OC(CCC(O)=O)=CN=2)N1C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C PQKVHTPFCCCSQI-UHFFFAOYSA-N 0.000 claims description 2
- CDZHQVMPXJJLNN-UHFFFAOYSA-N 3-[2-[4-(methylamino)-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound C1C(NC)CC(C=2SC(CCC(O)=O)=CN=2)N1C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C CDZHQVMPXJJLNN-UHFFFAOYSA-N 0.000 claims description 2
- KSARLWHBIDJEMO-UHFFFAOYSA-N 3-[2-[4-[ethyl(methyl)amino]-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound C1C(N(C)CC)CC(C=2SC(CCC(O)=O)=CN=2)N1C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C KSARLWHBIDJEMO-UHFFFAOYSA-N 0.000 claims description 2
- DTTWFONMOZZMBM-UHFFFAOYSA-N 3-[2-[4-amino-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2OC(CCC(O)=O)=CN=2)CC(N)C1 DTTWFONMOZZMBM-UHFFFAOYSA-N 0.000 claims description 2
- NPDHLKIQNQXBBG-UHFFFAOYSA-N 3-[2-[4-amino-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2SC(CCC(O)=O)=CN=2)CC(N)C1 NPDHLKIQNQXBBG-UHFFFAOYSA-N 0.000 claims description 2
- WAOFXRZHVRXLOH-UHFFFAOYSA-N 3-[2-[4-hydroxy-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2OC(CCC(O)=O)=CN=2)CC(O)C1 WAOFXRZHVRXLOH-UHFFFAOYSA-N 0.000 claims description 2
- ZWJDWVDJUGLXHM-UHFFFAOYSA-N 3-[2-[4-hydroxy-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2SC(CCC(O)=O)=CN=2)CC(O)C1 ZWJDWVDJUGLXHM-UHFFFAOYSA-N 0.000 claims description 2
- MRNHJCQSUAFKFC-UHFFFAOYSA-N 3-[2-[4-hydroxy-4-methyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2OC(CCC(O)=O)=CN=2)CC(C)(O)C1 MRNHJCQSUAFKFC-UHFFFAOYSA-N 0.000 claims description 2
- BFCLVYJXYNERGR-UHFFFAOYSA-N 3-[2-[4-hydroxy-4-methyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C=2SC(CCC(O)=O)=CN=2)CC(C)(O)C1 BFCLVYJXYNERGR-UHFFFAOYSA-N 0.000 claims description 2
- KNZKEYGBXFDQRG-UHFFFAOYSA-N 3-[2-[4-methyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound C1C(C)CC(C=2OC(CCC(O)=O)=CN=2)N1C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C KNZKEYGBXFDQRG-UHFFFAOYSA-N 0.000 claims description 2
- LRIWSKOJZQRLEW-UHFFFAOYSA-N 3-[2-[4-methyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound C1C(C)CC(C=2SC(CCC(O)=O)=CN=2)N1C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C LRIWSKOJZQRLEW-UHFFFAOYSA-N 0.000 claims description 2
- CDSKGEDQGNMWMK-UHFFFAOYSA-N 3-[2-[5,5-dimethyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C)(C)CCC1C1=NC=C(CCC(O)=O)O1 CDSKGEDQGNMWMK-UHFFFAOYSA-N 0.000 claims description 2
- MZNIOVGJBMHBII-UHFFFAOYSA-N 3-[2-[5,5-dimethyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C)(C)CCC1C1=NC=C(CCC(O)=O)S1 MZNIOVGJBMHBII-UHFFFAOYSA-N 0.000 claims description 2
- TUZOIXXJFYDJCL-UHFFFAOYSA-N 3-[2-[5-methyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound CC1CCC(C=2OC(CCC(O)=O)=CN=2)N1C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C TUZOIXXJFYDJCL-UHFFFAOYSA-N 0.000 claims description 2
- FZTAWKODGKJRID-UHFFFAOYSA-N 3-[2-[[[2-[4-[(2-chlorophenyl)carbamoylamino]phenyl]acetyl]amino]methyl]-1,3-thiazol-5-yl]propanoic acid Chemical compound S1C(CCC(=O)O)=CN=C1CNC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1Cl FZTAWKODGKJRID-UHFFFAOYSA-N 0.000 claims description 2
- GJPULSPYFFISLO-UHFFFAOYSA-N 3-[3-(2-methylpropyl)-2-oxo-4-[2-[4-(pyridin-2-ylcarbamoylamino)phenyl]acetyl]piperazin-1-yl]propanoic acid Chemical compound C1CN(CCC(O)=O)C(=O)C(CC(C)C)N1C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=N1 GJPULSPYFFISLO-UHFFFAOYSA-N 0.000 claims description 2
- IVRNBILFGWNELI-UHFFFAOYSA-N 3-[3-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-3,6-dihydro-2h-pyridin-2-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C2=NOC(CCC(O)=O)=C2)CC=CC1 IVRNBILFGWNELI-UHFFFAOYSA-N 0.000 claims description 2
- NKSYTVAHKMENLT-UHFFFAOYSA-N 3-[3-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-4-oxopyrrolidin-2-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C2=NOC(CCC(O)=O)=C2)CC(=O)C1 NKSYTVAHKMENLT-UHFFFAOYSA-N 0.000 claims description 2
- XVASUWDWKXEGLL-UHFFFAOYSA-N 3-[3-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]azepan-2-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C2=NOC(CCC(O)=O)=C2)CCCCC1 XVASUWDWKXEGLL-UHFFFAOYSA-N 0.000 claims description 2
- RANXAGPUOQGLBX-UHFFFAOYSA-N 3-[3-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]azetidin-2-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C2=NOC(CCC(O)=O)=C2)CC1 RANXAGPUOQGLBX-UHFFFAOYSA-N 0.000 claims description 2
- ROIHQGQZUMHJOQ-UHFFFAOYSA-N 3-[3-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]piperidin-2-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C2=NOC(CCC(O)=O)=C2)CCCC1 ROIHQGQZUMHJOQ-UHFFFAOYSA-N 0.000 claims description 2
- SMMKUWNIMVNLHW-UHFFFAOYSA-N 3-[3-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C2=NOC(CCC(O)=O)=C2)CCC1 SMMKUWNIMVNLHW-UHFFFAOYSA-N 0.000 claims description 2
- USEDUTJSKDZBGX-UHFFFAOYSA-N 3-[3-[1-[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,2-oxazol-5-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CC=2)C)C(OC)=CC=1CC(=O)NC(CC(C)C)C=1C=C(CCC(O)=O)ON=1 USEDUTJSKDZBGX-UHFFFAOYSA-N 0.000 claims description 2
- WNGIJWWXPVEZIA-UHFFFAOYSA-N 3-[3-[1-[[2-[4-[(2-fluorophenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,2,4-oxadiazol-5-yl]propanoic acid Chemical compound N=1OC(CCC(O)=O)=NC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1F WNGIJWWXPVEZIA-UHFFFAOYSA-N 0.000 claims description 2
- NDAOQILPGCTKAO-UHFFFAOYSA-N 3-[3-[1-[[2-[4-[(2-fluorophenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,2-oxazol-5-yl]propanoic acid Chemical compound C1=C(CCC(O)=O)ON=C1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1F NDAOQILPGCTKAO-UHFFFAOYSA-N 0.000 claims description 2
- FECUIVMNWPGAHF-UHFFFAOYSA-N 3-[3-[1-[[2-[4-[(2-fluorophenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-4,5-dihydro-1,2-oxazol-5-yl]propanoic acid Chemical compound N=1OC(CCC(O)=O)CC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1F FECUIVMNWPGAHF-UHFFFAOYSA-N 0.000 claims description 2
- NUIGIOAOIIEMLJ-UHFFFAOYSA-N 3-[3-[1-[[2-[4-[(2-methoxyphenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]pyrazol-1-yl]propanoic acid Chemical compound COC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)NC(CC(C)C)C1=NN(CCC(O)=O)C=C1 NUIGIOAOIIEMLJ-UHFFFAOYSA-N 0.000 claims description 2
- SADWDDUVTQJJOQ-UHFFFAOYSA-N 3-[3-[1-[[2-[4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,2-oxazol-5-yl]propanoic acid Chemical compound C1=C(CCC(O)=O)ON=C1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=NC=CC=C1C1CCCC1 SADWDDUVTQJJOQ-UHFFFAOYSA-N 0.000 claims description 2
- CPYREOPRIFPIDU-UHFFFAOYSA-N 3-[3-[2-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-3,4-dihydro-1h-isoquinolin-3-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C2=NOC(CCC(O)=O)=C2)CC2=CC=CC=C2C1 CPYREOPRIFPIDU-UHFFFAOYSA-N 0.000 claims description 2
- TXORLPKSRYMYPT-UHFFFAOYSA-N 3-[3-[2-methyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C2=NOC(CCC(O)=O)=C2)(C)CCC1 TXORLPKSRYMYPT-UHFFFAOYSA-N 0.000 claims description 2
- OJDDKEYLGQPWDS-UHFFFAOYSA-N 3-[3-[3,3-dimethyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C2=NOC(CCC(O)=O)=C2)C(C)(C)CC1 OJDDKEYLGQPWDS-UHFFFAOYSA-N 0.000 claims description 2
- FBWKPNCVKWNTMZ-UHFFFAOYSA-N 3-[3-[3-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-1,3-oxazolidin-4-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C2=NOC(CCC(O)=O)=C2)COC1 FBWKPNCVKWNTMZ-UHFFFAOYSA-N 0.000 claims description 2
- RGUDMEVSXGALPZ-UHFFFAOYSA-N 3-[3-[3-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-1,3-thiazolidin-4-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C2=NOC(CCC(O)=O)=C2)CSC1 RGUDMEVSXGALPZ-UHFFFAOYSA-N 0.000 claims description 2
- OQYAOHRTBOZRDJ-UHFFFAOYSA-N 3-[3-[3-methyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound CC1CCN(C(=O)CC=2C=CC(NC(=O)NC=3C(=CC=CC=3)C)=CC=2)C1C=1C=C(CCC(O)=O)ON=1 OQYAOHRTBOZRDJ-UHFFFAOYSA-N 0.000 claims description 2
- BAKRWGCOTCJFCK-UHFFFAOYSA-N 3-[3-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-1,2,4-oxadiazol-5-yl]propanoic acid Chemical compound N=1OC(CCC(O)=O)=NC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C BAKRWGCOTCJFCK-UHFFFAOYSA-N 0.000 claims description 2
- PWPUACJNJUPNMA-UHFFFAOYSA-N 3-[3-[4-(methylamino)-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound C1C(NC)CC(C2=NOC(CCC(O)=O)=C2)N1C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C PWPUACJNJUPNMA-UHFFFAOYSA-N 0.000 claims description 2
- PUPRDEGNEUYWIR-UHFFFAOYSA-N 3-[3-[4-amino-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C2=NOC(CCC(O)=O)=C2)CC(N)C1 PUPRDEGNEUYWIR-UHFFFAOYSA-N 0.000 claims description 2
- BNJAGPGSINHKFN-UHFFFAOYSA-N 3-[3-[4-hydroxy-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(C2=NOC(CCC(O)=O)=C2)CC(O)C1 BNJAGPGSINHKFN-UHFFFAOYSA-N 0.000 claims description 2
- ZYQRSODTOULYMV-UHFFFAOYSA-N 3-[3-[4-methyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound C1C(C)CC(C2=NOC(CCC(O)=O)=C2)N1C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C ZYQRSODTOULYMV-UHFFFAOYSA-N 0.000 claims description 2
- VDYXCQIYWYJORO-UHFFFAOYSA-N 3-[3-[5-methyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound CC1CCC(C2=NOC(CCC(O)=O)=C2)N1C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C VDYXCQIYWYJORO-UHFFFAOYSA-N 0.000 claims description 2
- ONJSTYHGGGDHFG-UHFFFAOYSA-N 3-[4-[1-[[2-[3-cyclopentyl-4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-3h-1,2,4-triazol-2-yl]propanoic acid Chemical compound C1N(CCC(O)=O)N=CN1C(CC(C)C)NC(=O)CC(C=C1C2CCCC2)=CC=C1NC(=O)NC1=NC=CC=C1C ONJSTYHGGGDHFG-UHFFFAOYSA-N 0.000 claims description 2
- HZVQGESZIRPWMS-UHFFFAOYSA-N 3-[4-[1-[[2-[3-cyclopentyl-4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-5h-tetrazol-1-yl]propanoic acid Chemical compound C1N(CCC(O)=O)N=NN1C(CC(C)C)NC(=O)CC(C=C1C2CCCC2)=CC=C1NC(=O)NC1=NC=CC=C1C HZVQGESZIRPWMS-UHFFFAOYSA-N 0.000 claims description 2
- RFYCZJUGAHKEFT-UHFFFAOYSA-N 3-[4-[1-[[2-[3-methoxy-4-(pyridin-2-ylcarbamoylamino)phenyl]acetyl]amino]-3-methylbutyl]-1,3-thiazol-2-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2N=CC=CC=2)C(OC)=CC=1CC(=O)NC(CC(C)C)C1=CSC(CCC(O)=O)=N1 RFYCZJUGAHKEFT-UHFFFAOYSA-N 0.000 claims description 2
- QMHGJGPKZYHUCW-UHFFFAOYSA-N 3-[4-[1-[[2-[3-methoxy-4-(pyridin-2-ylcarbamoylamino)phenyl]acetyl]amino]-3-methylbutyl]-3h-1,2,4-triazol-2-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2N=CC=CC=2)C(OC)=CC=1CC(=O)NC(CC(C)C)N1CN(CCC(O)=O)N=C1 QMHGJGPKZYHUCW-UHFFFAOYSA-N 0.000 claims description 2
- DZYDLVFEJZAFTB-UHFFFAOYSA-N 3-[4-[1-[[2-[3-methoxy-4-(pyridin-2-ylcarbamoylamino)phenyl]acetyl]amino]-3-methylbutyl]-5h-tetrazol-1-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2N=CC=CC=2)C(OC)=CC=1CC(=O)NC(CC(C)C)N1CN(CCC(O)=O)N=N1 DZYDLVFEJZAFTB-UHFFFAOYSA-N 0.000 claims description 2
- VQHWVJDNBDWGKE-UHFFFAOYSA-N 3-[4-[1-[[2-[3-methoxy-4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-3h-1,2,4-triazol-2-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CN=2)C)C(OC)=CC=1CC(=O)NC(CC(C)C)N1CN(CCC(O)=O)N=C1 VQHWVJDNBDWGKE-UHFFFAOYSA-N 0.000 claims description 2
- VECDKSXKQKNUSG-UHFFFAOYSA-N 3-[4-[1-[[2-[3-methoxy-4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-5h-tetrazol-1-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CN=2)C)C(OC)=CC=1CC(=O)NC(CC(C)C)N1CN(CCC(O)=O)N=N1 VECDKSXKQKNUSG-UHFFFAOYSA-N 0.000 claims description 2
- UMJKIVZGIFTIDK-UHFFFAOYSA-N 3-[4-[1-[[2-[3-methoxy-4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]imidazol-1-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CN=2)C)C(OC)=CC=1CC(=O)NC(CC(C)C)C1=CN(CCC(O)=O)C=N1 UMJKIVZGIFTIDK-UHFFFAOYSA-N 0.000 claims description 2
- KALHXHLPENMEFZ-UHFFFAOYSA-N 3-[4-[1-[[2-[4-[(2-methoxyphenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-3h-1,2,4-triazol-2-yl]propanoic acid Chemical compound COC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)NC(CC(C)C)N1C=NN(CCC(O)=O)C1 KALHXHLPENMEFZ-UHFFFAOYSA-N 0.000 claims description 2
- PGTOFLKFTMTKGW-UHFFFAOYSA-N 3-[4-[1-[[2-[4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]-3-(trifluoromethyl)phenyl]acetyl]amino]-3-methylbutyl]-5h-tetrazol-1-yl]propanoic acid Chemical compound C1N(CCC(O)=O)N=NN1C(CC(C)C)NC(=O)CC(C=C1C(F)(F)F)=CC=C1NC(=O)NC1=NC=CC=C1C1CCCC1 PGTOFLKFTMTKGW-UHFFFAOYSA-N 0.000 claims description 2
- JNBCCDKHITYYLN-UHFFFAOYSA-N 3-[4-[1-[[2-[4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]-3-methoxyphenyl]acetyl]amino]-3-methylbutyl]-3h-1,2,4-triazol-2-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CN=2)C2CCCC2)C(OC)=CC=1CC(=O)NC(CC(C)C)N1CN(CCC(O)=O)N=C1 JNBCCDKHITYYLN-UHFFFAOYSA-N 0.000 claims description 2
- JTRHOUGVQBQZDV-UHFFFAOYSA-N 3-[4-[1-[[2-[4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]-3-methoxyphenyl]acetyl]amino]-3-methylbutyl]-5h-tetrazol-1-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CN=2)C2CCCC2)C(OC)=CC=1CC(=O)NC(CC(C)C)N1CN(CCC(O)=O)N=N1 JTRHOUGVQBQZDV-UHFFFAOYSA-N 0.000 claims description 2
- RAUKOZAWRORVFI-UHFFFAOYSA-N 3-[4-[1-[[2-[4-[(3-methoxypyridin-2-yl)carbamoylamino]-3-methylphenyl]acetyl]amino]-3-methylbutyl]-1,1-dioxo-1,3-thiazol-2-yl]propanoic acid Chemical compound COC1=CC=CN=C1NC(=O)NC(C(=C1)C)=CC=C1CC(=O)NC(CC(C)C)C1=CS(=O)(=O)C(CCC(O)=O)=N1 RAUKOZAWRORVFI-UHFFFAOYSA-N 0.000 claims description 2
- VHXLSJBXWHGIQV-UHFFFAOYSA-N 3-[4-[2-[3-cyclopentyl-4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]-3-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound C1CN(CCC(O)=O)C(=O)C(CC(C)C)N1C(=O)CC(C=C1C2CCCC2)=CC=C1NC(=O)NC1=NC=CC=C1C VHXLSJBXWHGIQV-UHFFFAOYSA-N 0.000 claims description 2
- YMGABLQDYSLOCO-UHFFFAOYSA-N 3-[4-[2-[3-cyclopentyl-4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]-5-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound CC(C)CC1CN(CCC(O)=O)C(=O)CN1C(=O)CC(C=C1C2CCCC2)=CC=C1NC(=O)NC1=NC=CC=C1C YMGABLQDYSLOCO-UHFFFAOYSA-N 0.000 claims description 2
- XNTXPZBEHNQMKJ-UHFFFAOYSA-N 3-[4-[2-[3-fluoro-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-3-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound C1CN(CCC(O)=O)C(=O)C(CC(C)C)N1C(=O)CC(C=C1F)=CC=C1NC(=O)NC1=CC=CC=C1C XNTXPZBEHNQMKJ-UHFFFAOYSA-N 0.000 claims description 2
- GXTOANWOJIJYAX-UHFFFAOYSA-N 3-[4-[2-[3-fluoro-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-5-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound CC(C)CC1CN(CCC(O)=O)C(=O)CN1C(=O)CC(C=C1F)=CC=C1NC(=O)NC1=CC=CC=C1C GXTOANWOJIJYAX-UHFFFAOYSA-N 0.000 claims description 2
- NVBOGTVSBDXNFP-UHFFFAOYSA-N 3-[4-[2-[3-methoxy-4-(pyridin-2-ylcarbamoylamino)phenyl]acetyl]-3-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2N=CC=CC=2)C(OC)=CC=1CC(=O)N1CCN(CCC(O)=O)C(=O)C1CC(C)C NVBOGTVSBDXNFP-UHFFFAOYSA-N 0.000 claims description 2
- HSMYBTMFJUDUFX-UHFFFAOYSA-N 3-[4-[2-[3-methoxy-4-(pyridin-2-ylcarbamoylamino)phenyl]acetyl]-5-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2N=CC=CC=2)C(OC)=CC=1CC(=O)N1CC(=O)N(CCC(O)=O)CC1CC(C)C HSMYBTMFJUDUFX-UHFFFAOYSA-N 0.000 claims description 2
- BRIVWOYWSBAOCF-UHFFFAOYSA-N 3-[4-[2-[3-methoxy-4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]-3-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CN=2)C)C(OC)=CC=1CC(=O)N1CCN(CCC(O)=O)C(=O)C1CC(C)C BRIVWOYWSBAOCF-UHFFFAOYSA-N 0.000 claims description 2
- VPNPXXJZRDUNGA-UHFFFAOYSA-N 3-[4-[2-[3-methoxy-4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]-5-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CN=2)C)C(OC)=CC=1CC(=O)N1CC(=O)N(CCC(O)=O)CC1CC(C)C VPNPXXJZRDUNGA-UHFFFAOYSA-N 0.000 claims description 2
- VGNVEWADXOTTNV-UHFFFAOYSA-N 3-[4-[2-[4-[(2-methoxyphenyl)carbamoylamino]phenyl]acetyl]-3-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound COC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(CC(C)C)C(=O)N(CCC(O)=O)CC1 VGNVEWADXOTTNV-UHFFFAOYSA-N 0.000 claims description 2
- AHXUHEKVPJGXRM-UHFFFAOYSA-N 3-[4-[2-[4-[(2-methoxyphenyl)carbamoylamino]phenyl]acetyl]-5-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound COC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(CC(C)C)CN(CCC(O)=O)C(=O)C1 AHXUHEKVPJGXRM-UHFFFAOYSA-N 0.000 claims description 2
- DOKBDBCNJXMPLV-UHFFFAOYSA-N 3-[4-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-3-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound C1CN(CCC(O)=O)C(=O)C(CC(C)C)N1C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C DOKBDBCNJXMPLV-UHFFFAOYSA-N 0.000 claims description 2
- GWHJMWPJTHKXSP-UHFFFAOYSA-N 3-[4-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-5-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound CC(C)CC1CN(CCC(O)=O)C(=O)CN1C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C GWHJMWPJTHKXSP-UHFFFAOYSA-N 0.000 claims description 2
- OBSBZBGHXOLPKS-UHFFFAOYSA-N 3-[4-[2-[4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]-3-(trifluoromethyl)phenyl]acetyl]-3-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound C1CN(CCC(O)=O)C(=O)C(CC(C)C)N1C(=O)CC(C=C1C(F)(F)F)=CC=C1NC(=O)NC1=NC=CC=C1C1CCCC1 OBSBZBGHXOLPKS-UHFFFAOYSA-N 0.000 claims description 2
- PPYMJTNIYLVVQO-UHFFFAOYSA-N 3-[4-[2-[4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]-3-(trifluoromethyl)phenyl]acetyl]-5-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound CC(C)CC1CN(CCC(O)=O)C(=O)CN1C(=O)CC(C=C1C(F)(F)F)=CC=C1NC(=O)NC1=NC=CC=C1C1CCCC1 PPYMJTNIYLVVQO-UHFFFAOYSA-N 0.000 claims description 2
- YZXGRQCTXBPECV-UHFFFAOYSA-N 3-[4-[3-methyl-1-[[2-[4-(pyridin-2-ylcarbamoylamino)phenyl]acetyl]amino]butyl]-3h-1,2,4-triazol-2-yl]propanoic acid Chemical compound C1N(CCC(O)=O)N=CN1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=N1 YZXGRQCTXBPECV-UHFFFAOYSA-N 0.000 claims description 2
- IPGCTMDLMLSOIX-UHFFFAOYSA-N 3-[4-[3-methyl-1-[[2-[4-(pyridin-2-ylcarbamoylamino)phenyl]acetyl]amino]butyl]-5h-tetrazol-1-yl]propanoic acid Chemical compound C1N(CCC(O)=O)N=NN1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=N1 IPGCTMDLMLSOIX-UHFFFAOYSA-N 0.000 claims description 2
- WARMQJKGDVOFOL-UHFFFAOYSA-N 3-[4-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-3h-1,2,4-triazol-2-yl]propanoic acid Chemical compound C1N(CCC(O)=O)N=CN1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C WARMQJKGDVOFOL-UHFFFAOYSA-N 0.000 claims description 2
- UBBSKSBOGPHMQK-UHFFFAOYSA-N 3-[4-[n-acetyl-4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]-3-methoxyanilino]-3-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound COC1=CC(N(N2C(C(=O)N(CCC(O)=O)CC2)CC(C)C)C(C)=O)=CC=C1NC(=O)NC1=NC=CC=C1C1CCCC1 UBBSKSBOGPHMQK-UHFFFAOYSA-N 0.000 claims description 2
- VTBPQBWXMQHMNF-UHFFFAOYSA-N 3-[4-[n-acetyl-4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]-3-methoxyanilino]-5-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound COC1=CC(N(N2C(CN(CCC(O)=O)C(=O)C2)CC(C)C)C(C)=O)=CC=C1NC(=O)NC1=NC=CC=C1C1CCCC1 VTBPQBWXMQHMNF-UHFFFAOYSA-N 0.000 claims description 2
- SFLNLLXNHXFZLL-UHFFFAOYSA-N 3-[5-(2-methylpropyl)-2-oxo-4-[2-[4-(pyridin-2-ylcarbamoylamino)phenyl]acetyl]piperazin-1-yl]propanoic acid Chemical compound CC(C)CC1CN(CCC(O)=O)C(=O)CN1C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=N1 SFLNLLXNHXFZLL-UHFFFAOYSA-N 0.000 claims description 2
- FYPDRCFVOCSXCM-UHFFFAOYSA-N 3-[5-[1-[[2-[3-cyclopentyl-4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1h-imidazol-2-yl]propanoic acid Chemical compound C=1NC(CCC(O)=O)=NC=1C(CC(C)C)NC(=O)CC(C=C1C2CCCC2)=CC=C1NC(=O)NC1=NC=CC=C1C FYPDRCFVOCSXCM-UHFFFAOYSA-N 0.000 claims description 2
- SOIVRUNMXZJGFM-UHFFFAOYSA-N 3-[5-[1-[[2-[3-methoxy-4-(pyridin-2-ylcarbamoylamino)phenyl]acetyl]amino]-3-methylbutyl]-3,4-dihydropyrazol-2-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2N=CC=CC=2)C(OC)=CC=1CC(=O)NC(CC(C)C)C1=NN(CCC(O)=O)CC1 SOIVRUNMXZJGFM-UHFFFAOYSA-N 0.000 claims description 2
- PYEWNGLAQCNHET-UHFFFAOYSA-N 3-[5-[1-[[2-[3-methoxy-4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1h-imidazol-2-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CN=2)C)C(OC)=CC=1CC(=O)NC(CC(C)C)C1=CNC(CCC(O)=O)=N1 PYEWNGLAQCNHET-UHFFFAOYSA-N 0.000 claims description 2
- YXGKQOKTKJBMNF-UHFFFAOYSA-N 3-[5-[1-[[2-[4-[(2-methoxyphenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-3,4-dihydropyrazol-2-yl]propanoic acid Chemical compound COC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)NC(CC(C)C)C1=NN(CCC(O)=O)CC1 YXGKQOKTKJBMNF-UHFFFAOYSA-N 0.000 claims description 2
- PKVAVWDERVGHQQ-UHFFFAOYSA-N 3-[5-[1-[[2-[4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]-3-(trifluoromethyl)phenyl]acetyl]amino]-3-methylbutyl]-1h-imidazol-2-yl]propanoic acid Chemical compound C=1NC(CCC(O)=O)=NC=1C(CC(C)C)NC(=O)CC(C=C1C(F)(F)F)=CC=C1NC(=O)NC1=NC=CC=C1C1CCCC1 PKVAVWDERVGHQQ-UHFFFAOYSA-N 0.000 claims description 2
- JZJLELWKZMJEMH-UHFFFAOYSA-N 3-[5-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-3,4-dihydropyrazol-2-yl]propanoic acid Chemical compound N=1N(CCC(O)=O)CCC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C JZJLELWKZMJEMH-UHFFFAOYSA-N 0.000 claims description 2
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 claims description 2
- OBHPIMKIUKOKEI-UHFFFAOYSA-N 4-[2-[1-[[2-[3-fluoro-4-[(3-methoxypyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,3-thiazol-5-yl]butanoic acid Chemical compound COC1=CC=CN=C1NC(=O)NC(C(=C1)F)=CC=C1CC(=O)NC(CC(C)C)C1=NC=C(CCCC(O)=O)S1 OBHPIMKIUKOKEI-UHFFFAOYSA-N 0.000 claims description 2
- XMMXRZIFJXFUML-UHFFFAOYSA-N 4-[2-[1-[[2-[4-[(3-methoxypyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,3-oxazol-5-yl]butanoic acid Chemical compound COC1=CC=CN=C1NC(=O)NC(C=C1)=CC=C1CC(=O)NC(CC(C)C)C1=NC=C(CCCC(O)=O)O1 XMMXRZIFJXFUML-UHFFFAOYSA-N 0.000 claims description 2
- SNQJFFLWRHOZNB-UHFFFAOYSA-N 4-[3-[3-methyl-1-[[2-[4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]butyl]-1,2,4-oxadiazol-5-yl]butanoic acid Chemical compound N=1OC(CCCC(O)=O)=NC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=NC=CC=C1C SNQJFFLWRHOZNB-UHFFFAOYSA-N 0.000 claims description 2
- URQJBQWKWXFQTR-UHFFFAOYSA-N 4-[3-[3-methyl-1-[[2-[4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]butyl]-1,2-oxazol-5-yl]butanoic acid Chemical compound C1=C(CCCC(O)=O)ON=C1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=NC=CC=C1C URQJBQWKWXFQTR-UHFFFAOYSA-N 0.000 claims description 2
- FYVBJFUWKKXTGT-UHFFFAOYSA-N 4-[4-[1-[[2-[3-fluoro-4-[(3-methoxypyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,3-thiazol-2-yl]butanoic acid Chemical compound COC1=CC=CN=C1NC(=O)NC(C(=C1)F)=CC=C1CC(=O)NC(CC(C)C)C1=CSC(CCCC(O)=O)=N1 FYVBJFUWKKXTGT-UHFFFAOYSA-N 0.000 claims description 2
- WCIHXMYFPHAAHY-UHFFFAOYSA-N 4-[4-[1-[[2-[3-fluoro-4-[(3-methoxypyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-5h-tetrazol-1-yl]butanoic acid Chemical compound COC1=CC=CN=C1NC(=O)NC(C(=C1)F)=CC=C1CC(=O)NC(CC(C)C)N1N=NN(CCCC(O)=O)C1 WCIHXMYFPHAAHY-UHFFFAOYSA-N 0.000 claims description 2
- DYHHUGZZRVAGFD-UHFFFAOYSA-N 4-[4-[1-[[2-[4-[(3-methoxypyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-3h-1,2,4-triazol-2-yl]butanoic acid Chemical compound COC1=CC=CN=C1NC(=O)NC(C=C1)=CC=C1CC(=O)NC(CC(C)C)N1C=NN(CCCC(O)=O)C1 DYHHUGZZRVAGFD-UHFFFAOYSA-N 0.000 claims description 2
- OMINHUFLHSMCGZ-UHFFFAOYSA-N 4-[4-[1-[[2-[4-[(3-methoxypyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-5h-tetrazol-1-yl]butanoic acid Chemical compound COC1=CC=CN=C1NC(=O)NC(C=C1)=CC=C1CC(=O)NC(CC(C)C)N1N=NN(CCCC(O)=O)C1 OMINHUFLHSMCGZ-UHFFFAOYSA-N 0.000 claims description 2
- CBFSFTNBXNWFSS-UHFFFAOYSA-N 4-[4-[2-[3-fluoro-4-[(3-methoxypyridin-2-yl)carbamoylamino]phenyl]acetyl]-5-(2-methylpropyl)-2-oxopiperazin-1-yl]butanoic acid Chemical compound COC1=CC=CN=C1NC(=O)NC(C(=C1)F)=CC=C1CC(=O)N1C(CC(C)C)CN(CCCC(O)=O)C(=O)C1 CBFSFTNBXNWFSS-UHFFFAOYSA-N 0.000 claims description 2
- LJBAQXVDIKWONG-UHFFFAOYSA-N 4-[4-[2-[4-[(3-methoxypyridin-2-yl)carbamoylamino]phenyl]acetyl]-3-(2-methylpropyl)-2-oxopiperazin-1-yl]butanoic acid Chemical compound COC1=CC=CN=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(CC(C)C)C(=O)N(CCCC(O)=O)CC1 LJBAQXVDIKWONG-UHFFFAOYSA-N 0.000 claims description 2
- RJEHPZGTRPMDOK-UHFFFAOYSA-N 4-[4-[2-[4-[(3-methoxypyridin-2-yl)carbamoylamino]phenyl]acetyl]-5-(2-methylpropyl)-2-oxopiperazin-1-yl]butanoic acid Chemical compound COC1=CC=CN=C1NC(=O)NC(C=C1)=CC=C1CC(=O)N1C(CC(C)C)CN(CCCC(O)=O)C(=O)C1 RJEHPZGTRPMDOK-UHFFFAOYSA-N 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 2
- 230000001741 anti-phlogistic effect Effects 0.000 claims description 2
- 230000002682 anti-psoriatic effect Effects 0.000 claims description 2
- 229940030999 antipsoriatics Drugs 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 2
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 2
- 229960001438 immunostimulant agent Drugs 0.000 claims description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 229960000278 theophylline Drugs 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- IEZDMUDXYWGLBB-UHFFFAOYSA-N 2-[2-[3-methyl-1-[[2-[3-methyl-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-1,3-oxazol-5-yl]acetic acid Chemical compound N=1C=C(CC(O)=O)OC=1C(CC(C)C)NC(=O)CC(C=C1C)=CC=C1NC(=O)NC1=CC=CC=C1C IEZDMUDXYWGLBB-UHFFFAOYSA-N 0.000 claims 1
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 claims 1
- MPKGAIBNYQXEHK-UHFFFAOYSA-N 3-[2-[1-[[2-[4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]-3-(trifluoromethyl)phenyl]acetyl]amino]-3-methylbutyl]-1h-imidazol-5-yl]propanoic acid Chemical compound N=1C=C(CCC(O)=O)NC=1C(CC(C)C)NC(=O)CC(C=C1C(F)(F)F)=CC=C1NC(=O)NC1=NC=CC=C1C1CCCC1 MPKGAIBNYQXEHK-UHFFFAOYSA-N 0.000 claims 1
- XSKXLLSHYDMBTQ-UHFFFAOYSA-N 3-[2-[1-[[2-[4-[(3-methoxypyridin-2-yl)carbamoylamino]-3-methylphenyl]acetyl]amino]-3-methylbutyl]-1,1-dioxo-1,3-thiazol-5-yl]propanoic acid Chemical compound COC1=CC=CN=C1NC(=O)NC(C(=C1)C)=CC=C1CC(=O)NC(CC(C)C)C1=NC=C(CCC(O)=O)S1(=O)=O XSKXLLSHYDMBTQ-UHFFFAOYSA-N 0.000 claims 1
- FTEOLGBQNRKUKI-UHFFFAOYSA-N 3-[2-[3-methyl-1-[[2-[4-(phenylcarbamoylamino)phenyl]acetyl]amino]butyl]-1,3-thiazol-5-yl]propanoic acid Chemical compound N=1C=C(CCC(O)=O)SC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1 FTEOLGBQNRKUKI-UHFFFAOYSA-N 0.000 claims 1
- QETIBPGHECXVCR-UHFFFAOYSA-N 3-[3-[1-[[2-[4-[(2-chlorophenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,2-oxazol-5-yl]-3-oxopropanoic acid Chemical compound C1=C(C(=O)CC(O)=O)ON=C1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1Cl QETIBPGHECXVCR-UHFFFAOYSA-N 0.000 claims 1
- LEWNTBPCEVAZAE-UHFFFAOYSA-N 3-[3-[4-[ethyl(methyl)amino]-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound C1C(N(C)CC)CC(C2=NOC(CCC(O)=O)=C2)N1C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C LEWNTBPCEVAZAE-UHFFFAOYSA-N 0.000 claims 1
- VAXQMENAWHNIPP-UHFFFAOYSA-N 3-[4-[1-[[2-[4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]-3-methoxyphenyl]acetyl]amino]-3-methylbutyl]imidazol-1-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CN=2)C2CCCC2)C(OC)=CC=1CC(=O)NC(CC(C)C)C1=CN(CCC(O)=O)C=N1 VAXQMENAWHNIPP-UHFFFAOYSA-N 0.000 claims 1
- RXTGUHDQHLAPPP-UHFFFAOYSA-N 4-[4-[1-[[2-[3-fluoro-4-[(3-methoxypyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-3h-1,2,4-triazol-2-yl]butanoic acid Chemical compound COC1=CC=CN=C1NC(=O)NC(C(=C1)F)=CC=C1CC(=O)NC(CC(C)C)N1C=NN(CCCC(O)=O)C1 RXTGUHDQHLAPPP-UHFFFAOYSA-N 0.000 claims 1
- OBDWPMSWGSOCRH-UHFFFAOYSA-N 4-[4-[2-[3-fluoro-4-[(3-methoxypyridin-2-yl)carbamoylamino]phenyl]acetyl]-3-(2-methylpropyl)-2-oxopiperazin-1-yl]butanoic acid Chemical compound COC1=CC=CN=C1NC(=O)NC(C(=C1)F)=CC=C1CC(=O)N1C(CC(C)C)C(=O)N(CCCC(O)=O)CC1 OBDWPMSWGSOCRH-UHFFFAOYSA-N 0.000 claims 1
- 241001340534 Eido Species 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 90
- 230000015572 biosynthetic process Effects 0.000 description 71
- 238000003786 synthesis reaction Methods 0.000 description 71
- 239000007787 solid Substances 0.000 description 48
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 239000000203 mixture Substances 0.000 description 44
- 235000019439 ethyl acetate Nutrition 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- 230000002829 reductive effect Effects 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 25
- 239000007858 starting material Substances 0.000 description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 23
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 20
- 230000021164 cell adhesion Effects 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 235000002639 sodium chloride Nutrition 0.000 description 17
- 229960000583 acetic acid Drugs 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- 239000012044 organic layer Substances 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 15
- 101710178046 Chorismate synthase 1 Proteins 0.000 description 14
- 101710152695 Cysteine synthase 1 Proteins 0.000 description 14
- 102100032831 Protein ITPRID2 Human genes 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 14
- 235000019341 magnesium sulphate Nutrition 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 102000016359 Fibronectins Human genes 0.000 description 13
- 108010067306 Fibronectins Proteins 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 239000000376 reactant Substances 0.000 description 13
- 150000001412 amines Chemical class 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 108010044426 integrins Proteins 0.000 description 10
- 102000006495 integrins Human genes 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 7
- 125000001151 peptidyl group Chemical group 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 150000004702 methyl esters Chemical class 0.000 description 6
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 5
- 239000005977 Ethylene Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 5
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 241000701447 unidentified baculovirus Species 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- DDKMATGXLMCTOX-UHFFFAOYSA-N 2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetic acid Chemical compound CC1=CC=CC=C1NC(=O)NC1=CC=C(CC(O)=O)C=C1 DDKMATGXLMCTOX-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 150000002513 isocyanates Chemical class 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 150000003141 primary amines Chemical class 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 102100032817 Integrin alpha-5 Human genes 0.000 description 3
- 108010041014 Integrin alpha5 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 3
- 229910019213 POCl3 Inorganic materials 0.000 description 3
- 208000037273 Pathologic Processes Diseases 0.000 description 3
- 241000396922 Pontia daplidice Species 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 3
- OKROYDBQZXDOPP-UHFFFAOYSA-N benzyl n-(1-hydroxyimino-4-methylpentan-2-yl)carbamate Chemical compound CC(C)CC(C=NO)NC(=O)OCC1=CC=CC=C1 OKROYDBQZXDOPP-UHFFFAOYSA-N 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000013877 carbamide Nutrition 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 235000013861 fat-free Nutrition 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000012456 homogeneous solution Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 150000002923 oximes Chemical class 0.000 description 3
- 230000009054 pathological process Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- CSEWAUGPAQPMDC-UHFFFAOYSA-N 2-(4-aminophenyl)acetic acid Chemical compound NC1=CC=C(CC(O)=O)C=C1 CSEWAUGPAQPMDC-UHFFFAOYSA-N 0.000 description 2
- GZLZILJJCZAQPJ-UHFFFAOYSA-N 2-[2-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-4,5-dihydro-1,3-oxazol-5-yl]acetic acid Chemical compound N=1CC(CC(O)=O)OC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C GZLZILJJCZAQPJ-UHFFFAOYSA-N 0.000 description 2
- FEKYJFBLKLOKJW-UHFFFAOYSA-N 2-[3-benzyl-4-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-2-oxopiperazin-1-yl]propanoic acid Chemical compound O=C1N(C(C)C(O)=O)CCN(C(=O)CC=2C=CC(NC(=O)NC=3C(=CC=CC=3)C)=CC=2)C1CC1=CC=CC=C1 FEKYJFBLKLOKJW-UHFFFAOYSA-N 0.000 description 2
- CWWBJMAIDBRFLI-UHFFFAOYSA-N 2-[4-(pyridin-2-ylcarbamoylamino)phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1NC(=O)NC1=CC=CC=N1 CWWBJMAIDBRFLI-UHFFFAOYSA-N 0.000 description 2
- NJRXVEJTAYWCQJ-UHFFFAOYSA-L 2-mercaptosuccinate Chemical compound OC(=O)CC([S-])C([O-])=O NJRXVEJTAYWCQJ-UHFFFAOYSA-L 0.000 description 2
- ULNMNPMNICLRQB-UHFFFAOYSA-N 2-methyl-2-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]pentanoic acid Chemical compound C1=CC(CC(=O)NC(C)(CCC)C(O)=O)=CC=C1NC(=O)NC1=CC=CC=C1C ULNMNPMNICLRQB-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- ZRTVFODWHCWDGU-UHFFFAOYSA-N 3-[2-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-1,3-thiazol-5-yl]propanoic acid Chemical compound N=1C=C(CCC(O)=O)SC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C ZRTVFODWHCWDGU-UHFFFAOYSA-N 0.000 description 2
- LLHOYOCAAURYRL-UHFFFAOYSA-N 3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(O)C(C(O)=O)NC(=O)OC(C)(C)C LLHOYOCAAURYRL-UHFFFAOYSA-N 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- QOBGVINFWQEHNS-UHFFFAOYSA-N C1=CC(CC(=O)NC(CC(C)C)C(=O)NCC(O)CC(O)=O)=CC=C1NC(=O)NC1=CC=CC=C1C Chemical compound C1=CC(CC(=O)NC(CC(C)C)C(=O)NCC(O)CC(O)=O)=CC=C1NC(=O)NC1=CC=CC=C1C QOBGVINFWQEHNS-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100032818 Integrin alpha-4 Human genes 0.000 description 2
- 102100032816 Integrin alpha-6 Human genes 0.000 description 2
- 108010041100 Integrin alpha6 Proteins 0.000 description 2
- 108010030465 Integrin alpha6beta1 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- QCSFMCFHVGTLFF-NHCYSSNCSA-N Leu-Asp-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O QCSFMCFHVGTLFF-NHCYSSNCSA-N 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- 101710139349 Mucosal addressin cell adhesion molecule 1 Proteins 0.000 description 2
- 102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 229940022663 acetate Drugs 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 230000003113 alkalizing effect Effects 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 229960003328 benzoyl peroxide Drugs 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- FTSFFCCVEDHPPI-UHFFFAOYSA-N benzyl n-[1-[5-(diethoxymethyl)-1,2-oxazol-3-yl]-3-methylbutyl]carbamate Chemical compound O1C(C(OCC)OCC)=CC(C(CC(C)C)NC(=O)OCC=2C=CC=CC=2)=N1 FTSFFCCVEDHPPI-UHFFFAOYSA-N 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 2
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000006352 cycloaddition reaction Methods 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 2
- 150000004721 gamma keto acids Chemical class 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 108010046775 glutamyl-isoleucyl-leucyl-aspartyl-valine Proteins 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000005980 hexynyl group Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 229960003194 meglumine Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- UFARZHWBBNEGCJ-UHFFFAOYSA-N methyl 3-[2-[1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]propanoate Chemical compound S1C(CCC(=O)OC)=CN=C1C1N(C(=O)CC=2C=CC(NC(=O)NC=3C(=CC=CC=3)C)=CC=2)CCC1 UFARZHWBBNEGCJ-UHFFFAOYSA-N 0.000 description 2
- OUVYJTZCLNNLRJ-UHFFFAOYSA-N methyl 5-[[4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-4-oxopentanoate Chemical compound COC(=O)CCC(=O)CNC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1 OUVYJTZCLNNLRJ-UHFFFAOYSA-N 0.000 description 2
- UJYSYPVQHFNBML-UHFFFAOYSA-N methyl 5-aminolevulinate hydrochloride Chemical compound [Cl-].COC(=O)CCC(=O)C[NH3+] UJYSYPVQHFNBML-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 2
- 229950010765 pivalate Drugs 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 229960001755 resorcinol Drugs 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- AZAWJVQYVQHZAH-UHFFFAOYSA-N tert-butyl 2-[(5-methoxy-2,5-dioxopentyl)carbamoyl]pyrrolidine-1-carboxylate Chemical compound COC(=O)CCC(=O)CNC(=O)C1CCCN1C(=O)OC(C)(C)C AZAWJVQYVQHZAH-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CLRZFYOVDKRCGC-DQEYMECFSA-N (2s)-2-[[(2s)-3-(1h-indol-3-yl)-2-(phenylmethoxycarbonylamino)propanoyl]amino]-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C(=O)OCC1=CC=CC=C1 CLRZFYOVDKRCGC-DQEYMECFSA-N 0.000 description 1
- IDZGTFSDZJVMSD-UHFFFAOYSA-N (3-hydroxy-1-oxo-1-phenylmethoxybutan-2-yl)azanium;chloride Chemical compound Cl.CC(O)C(N)C(=O)OCC1=CC=CC=C1 IDZGTFSDZJVMSD-UHFFFAOYSA-N 0.000 description 1
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- FLNMCNFAJCMMHI-YGHIGYJTSA-N (4s)-4-amino-5-[[(2s,3s)-1-[[(2s)-1-[[(2s)-3-carboxy-1-[[(2s)-1-[(2s)-2-[[(2s)-1-[[(1s,2r)-1-carboxy-2-hydroxypropyl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan- Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FLNMCNFAJCMMHI-YGHIGYJTSA-N 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- IVKPLBITYAJWAU-UHFFFAOYSA-N 2-(carbamoylamino)-2-[2-(2-methylphenyl)phenyl]acetic acid Chemical compound CC1=CC=CC=C1C1=CC=CC=C1C(NC(N)=O)C(O)=O IVKPLBITYAJWAU-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- HPKFFZSXDWPVLX-UHFFFAOYSA-N 2-[(2-pyridin-1-ium-1-ylacetyl)amino]ethyl dodecanoate;chloride Chemical compound [Cl-].CCCCCCCCCCCC(=O)OCCNC(=O)C[N+]1=CC=CC=C1 HPKFFZSXDWPVLX-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- XTYBHEROISZNTD-UHFFFAOYSA-N 2-[2-[1-[[2-[4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]-3-fluorophenyl]acetyl]amino]-3-methylbutyl]-4,5-dihydro-1h-imidazol-5-yl]acetic acid Chemical compound N=1CC(CC(O)=O)NC=1C(CC(C)C)NC(=O)CC(C=C1F)=CC=C1NC(=O)NC1=NC=CC=C1C1CCCC1 XTYBHEROISZNTD-UHFFFAOYSA-N 0.000 description 1
- BOARBVDTOVVOBH-UHFFFAOYSA-N 2-[2-[3-methyl-1-[[2-[4-(pyridin-2-ylcarbamoylamino)phenyl]acetyl]amino]butyl]-1,3-thiazol-5-yl]propanoic acid Chemical compound N=1C=C(C(C)C(O)=O)SC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=N1 BOARBVDTOVVOBH-UHFFFAOYSA-N 0.000 description 1
- AHRWWIYRKRNMAL-UHFFFAOYSA-N 2-[2-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-1,3-oxazol-5-yl]propanoic acid Chemical compound N=1C=C(C(C)C(O)=O)OC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C AHRWWIYRKRNMAL-UHFFFAOYSA-N 0.000 description 1
- DLIMFHPTMXNHQT-UHFFFAOYSA-N 2-[3-[3-methyl-1-[[2-[4-(pyridin-2-ylcarbamoylamino)phenyl]acetyl]amino]butyl]-1,2-oxazol-5-yl]propanoic acid Chemical compound C1=C(C(C)C(O)=O)ON=C1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=N1 DLIMFHPTMXNHQT-UHFFFAOYSA-N 0.000 description 1
- RLMWOXIROXFCDP-UHFFFAOYSA-N 2-[4-[(4-methylpyridin-3-yl)carbamoylamino]phenyl]acetic acid Chemical compound CC1=CC=NC=C1NC(=O)NC1=CC=C(CC(O)=O)C=C1 RLMWOXIROXFCDP-UHFFFAOYSA-N 0.000 description 1
- CUIGSPBMMQWNLR-UHFFFAOYSA-N 2-isocyanatopyridine Chemical compound O=C=NC1=CC=CC=N1 CUIGSPBMMQWNLR-UHFFFAOYSA-N 0.000 description 1
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- NNGKLUDPNSDVKS-UHFFFAOYSA-N 2-o-tert-butyl 1-o-(2,5-dioxopyrrolidin-1-yl) pyrrolidine-1,2-dicarboxylate Chemical compound CC(C)(C)OC(=O)C1CCCN1C(=O)ON1C(=O)CCC1=O NNGKLUDPNSDVKS-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- MAVYKYRWYBBQGY-UHFFFAOYSA-N 2-pyrrolidin-1-yl-1,3-thiazole Chemical compound C1CCCN1C1=NC=CS1 MAVYKYRWYBBQGY-UHFFFAOYSA-N 0.000 description 1
- VAYMIYBJLRRIFR-UHFFFAOYSA-N 2-tolyl isocyanate Chemical compound CC1=CC=CC=C1N=C=O VAYMIYBJLRRIFR-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- RGUXEWWHSQGVRZ-UHFFFAOYSA-N 3,3-diethoxyprop-1-yne Chemical compound CCOC(C#C)OCC RGUXEWWHSQGVRZ-UHFFFAOYSA-N 0.000 description 1
- GYDIWFRXONNOOZ-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yl)-3-[3-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound O=C1C(CC(C)C)NCCN1C(CC(O)=O)C1=CC=C(OCO2)C2=C1 GYDIWFRXONNOOZ-UHFFFAOYSA-N 0.000 description 1
- UCDJLFDYXAQOHC-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yl)-3-[4-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-3-(2-methylpropyl)-2-oxopiperazin-1-yl]propanoic acid Chemical compound C1CN(C(CC(O)=O)C=2C=C3OCOC3=CC=2)C(=O)C(CC(C)C)N1C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C UCDJLFDYXAQOHC-UHFFFAOYSA-N 0.000 description 1
- OSJPSYSUFDOUID-UHFFFAOYSA-N 3-[2-[1-[[2-[3-methoxy-4-[(3-methoxypyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,1-dioxo-4,5-dihydro-1,3-thiazol-4-yl]propanoic acid Chemical compound COC1=CC=CN=C1NC(=O)NC(C(=C1)OC)=CC=C1CC(=O)NC(CC(C)C)C1=NC(CCC(O)=O)CS1(=O)=O OSJPSYSUFDOUID-UHFFFAOYSA-N 0.000 description 1
- WHCCWNJLZQTOKL-UHFFFAOYSA-N 3-[2-[1-[[2-[3-methoxy-4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1h-imidazol-5-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CN=2)C)C(OC)=CC=1CC(=O)NC(CC(C)C)C1=NC=C(CCC(O)=O)N1 WHCCWNJLZQTOKL-UHFFFAOYSA-N 0.000 description 1
- ZSYZFZYYPYUPPZ-UHFFFAOYSA-N 3-[2-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-1,3-thiazol-5-yl]prop-2-enoic acid Chemical compound N=1C=C(C=CC(O)=O)SC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C ZSYZFZYYPYUPPZ-UHFFFAOYSA-N 0.000 description 1
- AQDIZYOFALKWKC-UHFFFAOYSA-N 3-[2-[5-methyl-1-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound CC1CCC(C=2SC(CCC(O)=O)=CN=2)N1C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C AQDIZYOFALKWKC-UHFFFAOYSA-N 0.000 description 1
- DDIZICKYPKWZCZ-UHFFFAOYSA-N 3-[3-[1-[[2-[4-[(2-chlorophenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,2-oxazol-5-yl]propanoic acid Chemical compound C1=C(CCC(O)=O)ON=C1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1Cl DDIZICKYPKWZCZ-UHFFFAOYSA-N 0.000 description 1
- SHHRLUCDPPBOAL-UHFFFAOYSA-N 3-[3-[1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]cyclopentyl]-1,2-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)NC1(C2=NOC(CCC(O)=O)=C2)CCCC1 SHHRLUCDPPBOAL-UHFFFAOYSA-N 0.000 description 1
- CBDSZJRUVVLOGT-UHFFFAOYSA-N 3-[3-[1-[[2-[4-[(3-cyclopentylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-1,2,4-oxadiazol-5-yl]propanoic acid Chemical compound N=1OC(CCC(O)=O)=NC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=NC=CC=C1C1CCCC1 CBDSZJRUVVLOGT-UHFFFAOYSA-N 0.000 description 1
- DDKUBXQGJKJPEX-UHFFFAOYSA-N 3-[3-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-4,5-dihydro-1,2-oxazol-5-yl]propanoic acid Chemical compound N=1OC(CCC(O)=O)CC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C DDKUBXQGJKJPEX-UHFFFAOYSA-N 0.000 description 1
- MXZOXIFAKKCBMI-UHFFFAOYSA-N 3-[3-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]pyrazol-1-yl]propanoic acid Chemical compound C1=CN(CCC(O)=O)N=C1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C MXZOXIFAKKCBMI-UHFFFAOYSA-N 0.000 description 1
- DISMGGNSBGBMID-UHFFFAOYSA-N 3-[4-[1-[[2-[4-[(2-methoxyphenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-5h-tetrazol-1-yl]propanoic acid Chemical compound COC1=CC=CC=C1NC(=O)NC(C=C1)=CC=C1CC(=O)NC(CC(C)C)N1N=NN(CCC(O)=O)C1 DISMGGNSBGBMID-UHFFFAOYSA-N 0.000 description 1
- DMVSMWQZEWOISU-UHFFFAOYSA-N 3-[4-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-5h-tetrazol-1-yl]propanoic acid Chemical compound C1N(CCC(O)=O)N=NN1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C DMVSMWQZEWOISU-UHFFFAOYSA-N 0.000 description 1
- VCIHRPFJLVXZSU-UHFFFAOYSA-N 3-[5-(2-carboxyethyl)-3-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-4h-1,2-oxazol-5-yl]propanoic acid Chemical compound N=1OC(CCC(O)=O)(CCC(O)=O)CC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C VCIHRPFJLVXZSU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- PEZOIOCDCZQUCM-UHFFFAOYSA-N 3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)NCC(O)CC(O)=O PEZOIOCDCZQUCM-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- IGRPZULMBLQVFB-UHFFFAOYSA-N 4-[2-[1-[[2-[3-fluoro-4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-4,5-dihydro-1h-imidazol-5-yl]butanoic acid Chemical compound N=1CC(CCCC(O)=O)NC=1C(CC(C)C)NC(=O)CC(C=C1F)=CC=C1NC(=O)NC1=NC=CC=C1C IGRPZULMBLQVFB-UHFFFAOYSA-N 0.000 description 1
- AOBWHIBBSPTLRB-UHFFFAOYSA-N 4-[2-[3-methyl-1-[[2-[4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]butyl]-4,5-dihydro-1,3-oxazol-4-yl]butanoic acid Chemical compound N=1C(CCCC(O)=O)COC=1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=NC=CC=C1C AOBWHIBBSPTLRB-UHFFFAOYSA-N 0.000 description 1
- MTTJAKXIRMNNOV-UHFFFAOYSA-N 4-[3-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-1,2-oxazol-5-yl]butanoic acid Chemical compound C1=C(CCCC(O)=O)ON=C1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C MTTJAKXIRMNNOV-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
- USPFMEKVPDBMCG-UHFFFAOYSA-N 4-methyl-2-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound CC(C)CC(C(O)=O)NC(=O)OCC1=CC=CC=C1 USPFMEKVPDBMCG-UHFFFAOYSA-N 0.000 description 1
- JESCFDOKOINLCV-UHFFFAOYSA-N 4-methyl-2-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]pentanoic acid Chemical compound C1=CC(CC(=O)NC(CC(C)C)C(O)=O)=CC=C1NC(=O)NC1=CC=CC=C1C JESCFDOKOINLCV-UHFFFAOYSA-N 0.000 description 1
- OYNANFOWNSGDJL-UHFFFAOYSA-N 4-sulfanylpyrrolidin-1-ium-2-carboxylate Chemical compound OC(=O)C1CC(S)CN1 OYNANFOWNSGDJL-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 240000008025 Alternanthera ficoidea Species 0.000 description 1
- 239000004257 Anoxomer Substances 0.000 description 1
- 229920000239 Anoxomer Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- ZNSMNVMLTJELDZ-UHFFFAOYSA-N Bis(2-chloroethyl)ether Chemical compound ClCCOCCCl ZNSMNVMLTJELDZ-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- CRJPCFXDUJZWOJ-UHFFFAOYSA-M C(CC(=O)[O-])(=O)OCC.[Mg+] Chemical compound C(CC(=O)[O-])(=O)OCC.[Mg+] CRJPCFXDUJZWOJ-UHFFFAOYSA-M 0.000 description 1
- MNOHXUQUPLUEMI-UHFFFAOYSA-N CC(C)CC(NC(O)=O)C=1C=C(C=O)ON=1 Chemical compound CC(C)CC(NC(O)=O)C=1C=C(C=O)ON=1 MNOHXUQUPLUEMI-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000797623 Homo sapiens Protein AMBP Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010041012 Integrin alpha4 Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102400001240 Inter-alpha-trypsin inhibitor light chain Human genes 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- FAIXYKHYOGVFKA-UHFFFAOYSA-N Kinetin Natural products N=1C=NC=2N=CNC=2C=1N(C)C1=CC=CO1 FAIXYKHYOGVFKA-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- SHCSFZHSNSGTOP-UHFFFAOYSA-N Methyl 4-pentenoate Chemical compound COC(=O)CCC=C SHCSFZHSNSGTOP-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- HGINADPHJQTSKN-UHFFFAOYSA-N Monoethyl malonic acid Chemical compound CCOC(=O)CC(O)=O HGINADPHJQTSKN-UHFFFAOYSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 101001021261 Pedobacter heparinus (strain ATCC 13125 / DSM 2366 / CIP 104194 / JCM 7457 / NBRC 12017 / NCIMB 9290 / NRRL B-14731 / HIM 762-3) Heparin and heparin-sulfate lyase Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- SYCBXBCPLUFJID-UHFFFAOYSA-N Pramoxine hydrochloride Chemical compound Cl.C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 SYCBXBCPLUFJID-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- OLXXXTXQXUZABJ-UHFFFAOYSA-N S1C(CCC(=O)OC)=CN=C1C1N(C(O)=O)CCC1 Chemical compound S1C(CCC(=O)OC)=CN=C1C1N(C(O)=O)CCC1 OLXXXTXQXUZABJ-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 229910003074 TiCl4 Inorganic materials 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 230000008369 airway response Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 description 1
- 125000005154 alkyl sulfonyl amino alkyl group Chemical group 0.000 description 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940113720 aminosalicylate Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000019284 anoxomer Nutrition 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940053195 antiepileptics hydantoin derivative Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- QPMRSBCCSSENON-UHFFFAOYSA-N benzotriazol-1-yl diethyl phosphate Chemical compound C1=CC=C2N(OP(=O)(OCC)OCC)N=NC2=C1 QPMRSBCCSSENON-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- MBRRYUQWSOODEO-LBPRGKRZSA-N benzyl (2s)-2-amino-4-methylpentanoate Chemical compound CC(C)C[C@H](N)C(=O)OCC1=CC=CC=C1 MBRRYUQWSOODEO-LBPRGKRZSA-N 0.000 description 1
- LSSSQTLMVOVNIE-UHFFFAOYSA-N benzyl 3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound CC(C)(C)OC(=O)NCC(O)CC(=O)OCC1=CC=CC=C1 LSSSQTLMVOVNIE-UHFFFAOYSA-N 0.000 description 1
- ZLMOWTPALKKJHO-UHFFFAOYSA-N benzyl 4-methyl-2-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]pentanoate Chemical compound C=1C=CC=CC=1COC(=O)C(CC(C)C)NC(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C ZLMOWTPALKKJHO-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- SEWLQRPKYMZHDM-UHFFFAOYSA-N benzyl n-(4-methyl-1-oxopentan-2-yl)carbamate Chemical compound CC(C)CC(C=O)NC(=O)OCC1=CC=CC=C1 SEWLQRPKYMZHDM-UHFFFAOYSA-N 0.000 description 1
- IHYLXHUNQRWKPO-UHFFFAOYSA-N benzyl n-[1-(5-formyl-1,2-oxazol-3-yl)-3-methylbutyl]carbamate Chemical compound C1=C(C=O)ON=C1C(CC(C)C)NC(=O)OCC1=CC=CC=C1 IHYLXHUNQRWKPO-UHFFFAOYSA-N 0.000 description 1
- ALYUGLXUOFGIKV-UHFFFAOYSA-N benzyl n-[1-(hydroxyiminomethyl)cyclopentyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1(C=NO)CCCC1 ALYUGLXUOFGIKV-UHFFFAOYSA-N 0.000 description 1
- 150000004718 beta keto acids Chemical class 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- PIJXRNNCIJAUOX-UHFFFAOYSA-N butanoic acid;hydrochloride Chemical compound Cl.CCCC(O)=O PIJXRNNCIJAUOX-UHFFFAOYSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- QYCQIKPHQWHBKA-UHFFFAOYSA-N diethyl 4-methylideneheptanedioate Chemical compound CCOC(=O)CCC(=C)CCC(=O)OCC QYCQIKPHQWHBKA-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- UYAAVKFHBMJOJZ-UHFFFAOYSA-N diimidazo[1,3-b:1',3'-e]pyrazine-5,10-dione Chemical compound O=C1C2=CN=CN2C(=O)C2=CN=CN12 UYAAVKFHBMJOJZ-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 229940035422 diphenylamine Drugs 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000000555 dodecyl gallate Substances 0.000 description 1
- 235000010386 dodecyl gallate Nutrition 0.000 description 1
- 229940080643 dodecyl gallate Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229960000226 edetol Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- LFHGJZMSPRGLLC-UHFFFAOYSA-N ethyl 3-[3-(1-amino-3-methylbutyl)-1,2-oxazol-5-yl]-3-oxopropanoate;hydrochloride Chemical compound Cl.CCOC(=O)CC(=O)C1=CC(C(N)CC(C)C)=NO1 LFHGJZMSPRGLLC-UHFFFAOYSA-N 0.000 description 1
- JDIQDHRKMWFQDN-UHFFFAOYSA-N ethyl 3-[3-[3-methyl-1-[(2-methylpropan-2-yl)oxycarbonylamino]butyl]-1,2-oxazol-5-yl]-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)C1=CC(C(CC(C)C)NC(=O)OC(C)(C)C)=NO1 JDIQDHRKMWFQDN-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- YQGDEPYYFWUPGO-UHFFFAOYSA-N gamma-amino-beta-hydroxybutyric acid Chemical compound [NH3+]CC(O)CC([O-])=O YQGDEPYYFWUPGO-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 229960003258 hexylresorcinol Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- TVZISJTYELEYPI-UHFFFAOYSA-N hypodiphosphoric acid Chemical compound OP(O)(=O)P(O)(O)=O TVZISJTYELEYPI-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000008624 imidazolidinones Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003125 jurkat cell Anatomy 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical compound N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 description 1
- 229960001669 kinetin Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 229950000722 lapyrium chloride Drugs 0.000 description 1
- 229940061515 laureth-4 Drugs 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940040102 levulinic acid Drugs 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- NRHPUIXIIACACY-UHFFFAOYSA-N methyl 2-[2-[3-methyl-1-(phenylmethoxycarbonylamino)butyl]-1,3-thiazol-5-yl]propanoate Chemical compound S1C(C(C)C(=O)OC)=CN=C1C(CC(C)C)NC(=O)OCC1=CC=CC=C1 NRHPUIXIIACACY-UHFFFAOYSA-N 0.000 description 1
- OJOPDNGROFWSAM-UHFFFAOYSA-N methyl 3-(2-pyrrolidin-2-yl-1,3-thiazol-5-yl)propanoate Chemical compound S1C(CCC(=O)OC)=CN=C1C1NCCC1 OJOPDNGROFWSAM-UHFFFAOYSA-N 0.000 description 1
- VHZFCPVJKGKKDW-UHFFFAOYSA-N methyl 3-[2-[3-methyl-1-(phenylmethoxycarbonylamino)butyl]-1,3-oxazol-5-yl]propanoate Chemical compound O1C(CCC(=O)OC)=CN=C1C(CC(C)C)NC(=O)OCC1=CC=CC=C1 VHZFCPVJKGKKDW-UHFFFAOYSA-N 0.000 description 1
- SSRSKEIGDLQCKU-UHFFFAOYSA-N methyl 3-[3-(2-methylpropyl)-2-oxopiperazin-1-yl]butanoate Chemical compound COC(=O)CC(C)N1CCNC(CC(C)C)C1=O SSRSKEIGDLQCKU-UHFFFAOYSA-N 0.000 description 1
- ADNCANHBORGAOU-UHFFFAOYSA-N methyl 3-[3-[3-methyl-1-(phenylmethoxycarbonylamino)butyl]-1,2-oxazol-5-yl]propanoate Chemical compound O1C(CCC(=O)OC)=CC(C(CC(C)C)NC(=O)OCC=2C=CC=CC=2)=N1 ADNCANHBORGAOU-UHFFFAOYSA-N 0.000 description 1
- XCXHOENYCOFTRI-UHFFFAOYSA-N methyl 3-[3-[3-methyl-1-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]butyl]-1,2-oxazol-5-yl]propanoate Chemical compound O1C(CCC(=O)OC)=CC(C(CC(C)C)NC(=O)CC=2C=CC(NC(=O)NC=3C(=CC=CC=3)C)=CC=2)=N1 XCXHOENYCOFTRI-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960003476 methylparaben sodium Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical class O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical class O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical class O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 229940019974 pramoxine hydrochloride Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940116423 propylene glycol diacetate Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- NDGRWYRVNANFNB-UHFFFAOYSA-N pyrazolidin-3-one Chemical class O=C1CCNN1 NDGRWYRVNANFNB-UHFFFAOYSA-N 0.000 description 1
- OAWXZFGKDDFTGS-UHFFFAOYSA-N pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)C1CCCN1C(O)=O OAWXZFGKDDFTGS-UHFFFAOYSA-N 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-N sodium;2-hydroxybenzoic acid Chemical compound [Na+].OC(=O)C1=CC=CC=C1O ABBQHOQBGMUPJH-UHFFFAOYSA-N 0.000 description 1
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- 229940044609 sulfur dioxide Drugs 0.000 description 1
- IXPAAHZTOUOJJM-UHFFFAOYSA-N sulfuryl chloride fluoride Chemical compound FS(Cl)(=O)=O IXPAAHZTOUOJJM-UHFFFAOYSA-N 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LTBBIDJBIFBPGK-UHFFFAOYSA-N tert-butyl 2-[5-(3-methoxy-3-oxopropyl)-1,3-thiazol-2-yl]pyrrolidine-1-carboxylate Chemical compound S1C(CCC(=O)OC)=CN=C1C1N(C(=O)OC(C)(C)C)CCC1 LTBBIDJBIFBPGK-UHFFFAOYSA-N 0.000 description 1
- NBRKLOOSMBRFMH-UHFFFAOYSA-N tert-butyl chloride Chemical class CC(C)(C)Cl NBRKLOOSMBRFMH-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/58—One oxygen atom, e.g. butenolide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9118098P | 1998-06-30 | 1998-06-30 | |
PCT/IB1999/000973 WO2000000477A1 (en) | 1998-06-30 | 1999-05-31 | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20000917A2 true HRP20000917A2 (en) | 2002-02-28 |
Family
ID=22226483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20000917A HRP20000917A2 (en) | 1998-06-30 | 2000-12-29 | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
Country Status (37)
Country | Link |
---|---|
US (2) | US6355662B1 (es) |
EP (1) | EP1091943B1 (es) |
JP (1) | JP3676677B2 (es) |
KR (1) | KR20010083081A (es) |
CN (1) | CN1308616A (es) |
AP (1) | AP1236A (es) |
AR (1) | AR015312A1 (es) |
AT (1) | ATE311371T1 (es) |
AU (1) | AU758939B2 (es) |
BG (1) | BG105190A (es) |
BR (1) | BR9911701A (es) |
CA (1) | CA2336625A1 (es) |
CO (1) | CO5320599A1 (es) |
CZ (1) | CZ20004909A3 (es) |
DE (1) | DE69928667T2 (es) |
EA (1) | EA004792B1 (es) |
GT (1) | GT199900101A (es) |
HN (1) | HN1999000099A (es) |
HR (1) | HRP20000917A2 (es) |
HU (1) | HUP0102477A3 (es) |
ID (1) | ID27414A (es) |
IL (1) | IL139584A0 (es) |
IS (1) | IS5720A (es) |
MA (1) | MA26640A1 (es) |
NO (1) | NO20006600L (es) |
NZ (1) | NZ508033A (es) |
OA (1) | OA11577A (es) |
PA (1) | PA8477001A1 (es) |
PE (1) | PE20000762A1 (es) |
PL (1) | PL345308A1 (es) |
SK (1) | SK20052000A3 (es) |
TN (1) | TNSN99110A1 (es) |
TR (1) | TR200003848T2 (es) |
UA (1) | UA66864C2 (es) |
WO (1) | WO2000000477A1 (es) |
YU (1) | YU77600A (es) |
ZA (1) | ZA993777B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6992107B1 (en) | 1995-03-10 | 2006-01-31 | Photocure Asa | Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy |
AU746963B2 (en) | 1998-06-12 | 2002-05-09 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Imidazolyl derivatives |
OA11577A (en) * | 1998-06-30 | 2004-07-26 | Pfizer Prod Inc | Non-peptidyl inhibitors of VLA-4 dependent cell vinding useful in treating inflammatory, autoimmune,and respiratory diseases. |
US6518292B1 (en) * | 1999-03-12 | 2003-02-11 | Bristol-Myers Squibb Co. | Heterocyclic aromatic compounds usefuls as growth hormone secretagogues |
JP2003503350A (ja) * | 1999-06-30 | 2003-01-28 | 第一製薬株式会社 | Vla−4インヒビター化合物 |
US6756378B2 (en) * | 1999-06-30 | 2004-06-29 | Pharmacopeia Drug Discovery, Inc. | VLA-4 inhibitor compounds |
NZ518886A (en) * | 1999-12-28 | 2004-02-27 | Pfizer Prod Inc | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
AU2001234741A1 (en) * | 2000-02-04 | 2001-08-14 | Biogen, Inc. | Integrin antagonists |
CA2413418A1 (en) | 2000-06-21 | 2001-12-27 | Joseph B. Santella | Piperidine amides as modulators of chemokine receptor activity |
JP2004518613A (ja) * | 2000-08-01 | 2004-06-24 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | イミダゾリル誘導体 |
GB2367816A (en) | 2000-10-09 | 2002-04-17 | Bayer Ag | Urea- and thiourea-containing derivatives of beta-amino acids |
TWI312779B (es) | 2000-12-28 | 2009-08-01 | Daiichi Seiyaku Co | |
DE10111877A1 (de) * | 2001-03-10 | 2002-09-12 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
ATE408593T1 (de) | 2001-05-03 | 2008-10-15 | Galileo Lab Inc | Pyruvatderivate |
ES2296926T3 (es) * | 2001-06-06 | 2008-05-01 | Aventis Pharma Limited | Tetrahidroisoquinolinas sustituidas para usar en el tratamiento de enfermedades inflamatorias. |
GB2377933A (en) | 2001-07-06 | 2003-01-29 | Bayer Ag | Succinic acid derivatives useful as integrin antagonists |
DE10137595A1 (de) | 2001-08-01 | 2003-02-13 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung |
US6974869B2 (en) * | 2001-09-18 | 2005-12-13 | Bristol-Myers Squibb Pharma Company | Piperizinones as modulators of chemokine receptor activity |
CA2488117A1 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
PL374860A1 (en) | 2002-07-09 | 2005-11-14 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
MXPA06000850A (es) | 2003-07-24 | 2006-03-30 | Daiichi Seiyaku Co | Compuesto de acido ciclohexancarboxilico. |
GB0402812D0 (en) * | 2004-02-09 | 2004-03-10 | Tanabe Seiyaku Co | Novel compounds |
US7309709B2 (en) * | 2004-04-01 | 2007-12-18 | Pfizer Inc. | Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders |
TW200610754A (en) * | 2004-06-14 | 2006-04-01 | Daiichi Seiyaku Co | Vla-4 inhibitor |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
WO2007069635A1 (ja) | 2005-12-13 | 2007-06-21 | Daiichi Sankyo Company, Limited | Vla-4阻害薬 |
WO2011020874A1 (en) | 2009-08-20 | 2011-02-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
JP7210540B2 (ja) | 2017-08-04 | 2023-01-23 | 武田薬品工業株式会社 | 血漿カリクレインの阻害剤およびその使用 |
US20240301512A1 (en) | 2021-01-29 | 2024-09-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5294713A (en) * | 1991-08-23 | 1994-03-15 | Takeda Chemical Industries, Ltd. | 2-piperazinone compounds and their use |
US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
OA11577A (en) * | 1998-06-30 | 2004-07-26 | Pfizer Prod Inc | Non-peptidyl inhibitors of VLA-4 dependent cell vinding useful in treating inflammatory, autoimmune,and respiratory diseases. |
-
1999
- 1999-05-31 OA OA1200000361A patent/OA11577A/en unknown
- 1999-05-31 PL PL99345308A patent/PL345308A1/xx not_active Application Discontinuation
- 1999-05-31 AT AT99921046T patent/ATE311371T1/de not_active IP Right Cessation
- 1999-05-31 CZ CZ20004909A patent/CZ20004909A3/cs unknown
- 1999-05-31 KR KR1020007015120A patent/KR20010083081A/ko active IP Right Grant
- 1999-05-31 HU HU0102477A patent/HUP0102477A3/hu unknown
- 1999-05-31 UA UA2000127651A patent/UA66864C2/uk unknown
- 1999-05-31 CA CA002336625A patent/CA2336625A1/en not_active Abandoned
- 1999-05-31 DE DE69928667T patent/DE69928667T2/de not_active Expired - Fee Related
- 1999-05-31 AU AU38416/99A patent/AU758939B2/en not_active Ceased
- 1999-05-31 ID IDW20002723A patent/ID27414A/id unknown
- 1999-05-31 EP EP99921046A patent/EP1091943B1/en not_active Expired - Lifetime
- 1999-05-31 IL IL13958499A patent/IL139584A0/xx unknown
- 1999-05-31 CN CN99808134A patent/CN1308616A/zh active Pending
- 1999-05-31 TR TR2000/03848T patent/TR200003848T2/xx unknown
- 1999-05-31 WO PCT/IB1999/000973 patent/WO2000000477A1/en not_active Application Discontinuation
- 1999-05-31 EA EA200001238A patent/EA004792B1/ru not_active IP Right Cessation
- 1999-05-31 SK SK2005-2000A patent/SK20052000A3/sk unknown
- 1999-05-31 NZ NZ508033A patent/NZ508033A/xx unknown
- 1999-05-31 JP JP2000557238A patent/JP3676677B2/ja not_active Expired - Fee Related
- 1999-05-31 US US09/403,846 patent/US6355662B1/en not_active Expired - Fee Related
- 1999-05-31 BR BR9911701-0A patent/BR9911701A/pt not_active IP Right Cessation
- 1999-05-31 YU YU77600A patent/YU77600A/sh unknown
- 1999-06-03 AP APAP/P/1999/001561A patent/AP1236A/en active
- 1999-06-04 ZA ZA9903777A patent/ZA993777B/xx unknown
- 1999-06-07 MA MA25611A patent/MA26640A1/fr unknown
- 1999-06-09 TN TNTNSN99110A patent/TNSN99110A1/fr unknown
- 1999-06-16 AR ARP990102883A patent/AR015312A1/es not_active Application Discontinuation
- 1999-06-17 HN HN1999000099A patent/HN1999000099A/es unknown
- 1999-06-23 US US09/338,832 patent/US6306887B1/en not_active Expired - Fee Related
- 1999-06-25 PE PE1999000583A patent/PE20000762A1/es not_active Application Discontinuation
- 1999-06-25 GT GT199900101A patent/GT199900101A/es unknown
- 1999-06-29 PA PA19998477001A patent/PA8477001A1/es unknown
- 1999-06-30 CO CO99040934A patent/CO5320599A1/es not_active Application Discontinuation
-
2000
- 2000-11-21 IS IS5720A patent/IS5720A/is unknown
- 2000-12-22 NO NO20006600A patent/NO20006600L/no not_active Application Discontinuation
- 2000-12-29 HR HR20000917A patent/HRP20000917A2/hr not_active Application Discontinuation
-
2001
- 2001-01-26 BG BG105190A patent/BG105190A/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20000917A2 (en) | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | |
US6667331B2 (en) | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | |
JP6430398B2 (ja) | ベンジルアミン誘導体 | |
CA2988147C (en) | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders | |
AU2009273105B2 (en) | Azole compound | |
KR20080012304A (ko) | 피라졸 화합물 및 이들 피라졸 화합물을 포함하여이루어지는 당뇨병 치료약 | |
CZ374397A3 (cs) | Isoxazolinové a isoxazolové sloučeniny, způsob jejich výroby a farmaceutické prostředky na jejich bázi | |
JPH072851A (ja) | 5員複素環化合物、それらの調製方法及びこれらの化合物を含む医薬組成物 | |
KR101046039B1 (ko) | 프로판-1,3-디온 유도체 또는 그의 염 | |
US5710159A (en) | Integrin receptor antagonists | |
KR20100044251A (ko) | 특정 화학 물질, 조성물 및 방법 | |
EP3077380B1 (en) | Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase | |
CA3162388A1 (en) | 4-phenyl-n-(phenyl)thiazol-2-amine derivatives and related compounds as aryl hydrocarbon receptor (ahr) agonists for the treatment of e.g. angiogenesis implicated or inflammatory disorder | |
MXPA00012625A (es) | Inhibidores no peptidilicos de la union a las celulas dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias | |
MXPA02006599A (es) | Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatoiras, autoinmunes y respiratoiras |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
A1OB | Publication of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20040407 Year of fee payment: 6 |
|
OBST | Application withdrawn |